Olfactory ensheathing cells	1
GDNF	61
spinal cord repair Li Cao ,1 Li Liu ,1,2 Zhe-Yu Chen ,1 Li-Mei Wang ,1 Jun-Li Ye ,1,2 Hai-Yan Qiu ,1,2 Chang-Lin Lu1	77
spinal cord repair Li Cao ,1 Li Liu	77
spinal cord repair Li Cao	77
,1 Li Liu	102
,1,2 Zhe-Yu Chen ,1 Li-Mei Wang	111
,1,2 Zhe-Yu Chen ,1	111
Li-Mei Wang	130
,1 Jun-Li	141
Ye ,1,2 Hai-Yan Qiu ,1,2 Chang-Lin Lu1	151
Ye	151
,1,2 Hai-Yan Qiu ,1,2 Chang-Lin Lu1	153
and Cheng He1 1Department of Neurobiology , Second Military Medical University , Shanghai 200433 and 2Department	192
Cheng He1 1Department of Neurobiology , Second Military Medical University , Shanghai 200433 and 2Department	196
Cheng He1 1Department	196
Neurobiology , Second Military Medical University , Shanghai 200433 and 2Department	221
Neurobiology	221
Second Military Medical University	235
Shanghai 200433	271
2Department	291
Pathophysiology , Qingdao Medical College of Qingdao University , Shandong 266021 , China	306
Pathophysiology	306
Qingdao Medical College of Qingdao University	323
Qingdao Medical College	323
Qingdao University	350
Shandong 266021 , China	370
Shandong 266021	370
China	387
Li Cao and Li Liu	394
the study Correspondence	435
: Cheng He , Department of Neurobiology , Second Military Medical University , Shanghai 200433 , China E-mail : chenghe@online.sh.cn Summary Olfactory ensheathing cell -LRB- OEC -RRB-	462
Cheng He	464
Cheng	464
He	470
Department of Neurobiology , Second Military Medical University , Shanghai 200433 , China E-mail	474
Department	474
Neurobiology , Second Military Medical University , Shanghai 200433 , China E-mail	488
Neurobiology	488
Second Military Medical University	502
Shanghai 200433	538
China E-mail	555
chenghe@online.sh.cn Summary Olfactory ensheathing cell -LRB- OEC -RRB-	569
chenghe@online.sh.cn	569
Summary Olfactory ensheathing cell -LRB- OEC -RRB-	591
Summary Olfactory ensheathing cell	591
OEC	627
transplantation	632
a very promising therapy for spinal cord repair	663
a very promising therapy	663
spinal cord repair	692
this study	715
we	727
the ability of genetically modified OECs	737
the ability	737
genetically modified OECs	752
high levels of glial cell linederived neurotrophic factor -LRB- GDNF -RRB- to promote spinal cord repair	789
high levels	789
glial cell linederived neurotrophic factor -LRB- GDNF -RRB- to promote spinal cord repair	804
glial cell	804
neurotrophic factor -LRB- GDNF -RRB-	827
neurotrophic factor	827
GDNF	848
spinal cord repair	865
The GDNF gene	885
OECs using a retroviral-based system	919
OECs	919
a retroviral-based system	930
The engineered OECs	957
their ability to express and secrete biologically active GDNF in vitro	1005
biologically active GDNF	1042
implantation into the spinal cord of adult rats with complete spinal cord transection	1083
implantation	1083
the spinal cord of adult rats with complete spinal cord transection	1101
the spinal cord	1101
adult rats with complete spinal cord transection	1120
adult rats	1120
complete spinal cord transection	1136
OEC survival and GDNF production	1170
OEC survival	1170
GDNF production	1187
The locomotor functions of animals	1218
The locomotor functions	1218
animals	1245
axon regeneration	1271
the morphological level	1306
our knowledge	1334
we	1349
the first time	1363
the genetically modified OECs	1383
GDNF in vivo	1438
GDNF	1438
vivo	1446
recovery	1476
spinal cord injury -LRB- SCI -RRB-	1491
spinal cord injury	1491
SCI	1511
This work combined the outgrowthpromoting property of OECs with the neuroprotective effects of the	1517
This work	1517
the outgrowthpromoting property of OECs	1536
the outgrowthpromoting property	1536
OECs	1571
the neuroprotective effects of the	1581
the neuroprotective effects	1581
the	1612
neurotrophic factors	1643
new avenues	1674
the treatment of SCI	1690
the treatment	1690
SCI	1707
Keywords : spinal cord injury ; olfactory ensheathing cell ; glial cell line-derived neurotrophic factor ; transplantation ; gene therapy Abbreviations : CM = conditioned medium ; CSN = corticospinal neuron ; CST = corticospinal tract ; DMEM = Dulbecco 's modified Eagle medium ; GDNF = glial cell line-derived neurotrophic factor ; GDNF = glial cell line-derived neurotrophic factor ; GFAP = glial fibrillary acidic protein ; GFP = green ¯ uorescent protein ; HRP = horseradish peroxidase ; LTR = long terminal repeat ; NF = neurofilament ; OECs = olfactory ensheathing cells ; PBS = phosphate-buffered saline ; RSN = rubrospinal neuron ; SCI = spinal cord injury	1712
Keywords	1712
spinal cord injury ; olfactory ensheathing cell ; glial cell line-derived neurotrophic factor ; transplantation ; gene therapy Abbreviations : CM = conditioned medium ; CSN = corticospinal neuron ; CST = corticospinal tract ; DMEM = Dulbecco 's modified Eagle medium ; GDNF = glial cell line-derived neurotrophic factor ; GDNF = glial cell line-derived neurotrophic factor ; GFAP = glial fibrillary acidic protein ; GFP = green ¯ uorescent protein ; HRP = horseradish peroxidase ; LTR = long terminal repeat ; NF = neurofilament ; OECs = olfactory ensheathing cells ; PBS = phosphate-buffered saline ; RSN = rubrospinal neuron ; SCI = spinal cord injury	1722
spinal cord injury ; olfactory ensheathing cell ; glial cell line-derived neurotrophic factor ; transplantation ; gene therapy Abbreviations : CM = conditioned medium ; CSN = corticospinal neuron ; CST = corticospinal tract	1722
spinal cord injury ; olfactory ensheathing cell	1722
spinal cord injury	1722
olfactory ensheathing cell	1742
glial cell line-derived neurotrophic factor	1770
glial cell	1770
line-derived neurotrophic factor	1781
transplantation ; gene therapy Abbreviations	1815
transplantation	1815
gene therapy Abbreviations	1832
CM = conditioned medium	1861
CM	1861
CSN = corticospinal neuron	1886
CSN	1886
= corticospinal neuron	1890
CST = corticospinal tract	1914
CST	1914
= corticospinal tract	1918
DMEM = Dulbecco 's modified Eagle medium ; GDNF = glial cell line-derived neurotrophic factor ; GDNF = glial cell line-derived neurotrophic factor ; GFAP = glial fibrillary acidic protein ; GFP = green ¯ uorescent protein ; HRP = horseradish peroxidase ; LTR = long terminal repeat ; NF = neurofilament ; OECs = olfactory ensheathing cells ; PBS = phosphate-buffered saline ; RSN = rubrospinal neuron ; SCI = spinal cord injury	1941
DMEM	1941
Dulbecco 's modified Eagle medium ; GDNF = glial cell line-derived neurotrophic factor ; GDNF = glial cell line-derived neurotrophic factor ; GFAP = glial fibrillary acidic protein ; GFP = green ¯ uorescent protein ; HRP = horseradish peroxidase ; LTR = long terminal repeat ; NF = neurofilament ; OECs = olfactory ensheathing cells ; PBS = phosphate-buffered saline ; RSN = rubrospinal neuron ; SCI = spinal cord injury	1948
Dulbecco 's modified Eagle medium	1948
Dulbecco 's	1948
GDNF = glial cell line-derived neurotrophic factor ; GDNF = glial cell line-derived neurotrophic factor ; GFAP = glial fibrillary acidic protein ; GFP = green ¯ uorescent protein ; HRP = horseradish peroxidase ; LTR = long terminal repeat ; NF = neurofilament ; OECs = olfactory ensheathing cells ; PBS = phosphate-buffered saline ; RSN = rubrospinal neuron ; SCI = spinal cord injury	1982
GDNF = glial cell line-derived neurotrophic factor	1982
GDNF = glial cell	1982
line-derived neurotrophic factor	2000
GDNF = glial cell line-derived neurotrophic factor	2034
GDNF = glial cell	2034
line-derived neurotrophic factor	2052
GFAP = glial fibrillary acidic protein	2086
GFAP	2086
= glial fibrillary acidic protein	2091
GFP = green ¯ uorescent protein	2126
GFP = green ¯	2126
uorescent protein	2139
HRP = horseradish peroxidase	2158
HRP	2158
= horseradish peroxidase	2162
LTR = long terminal repeat	2188
LTR	2188
= long terminal repeat	2192
NF = neurofilament	2216
NF	2216
= neurofilament	2219
OECs = olfactory ensheathing cells	2236
OECs	2236
= olfactory ensheathing cells	2241
PBS = phosphate-buffered saline	2272
PBS	2272
= phosphate-buffered saline	2276
RSN = rubrospinal neuron	2305
RSN	2305
= rubrospinal neuron	2309
SCI = spinal cord injury	2331
SCI	2331
= spinal cord injury	2335
August 4 , 2003	2365
October 23 , 2003 Accepted October 24 , 2003	2389
October 23 , 2003	2389
October 24 , 2003	2415
Advanced Access publication December 22	2433
Advanced Access publication	2433
December 22	2461
2003 Introduction Spinal cord injury	2474
2003 Introduction	2474
Spinal cord injury	2494
SCI	2514
one of the most devastating forms of trauma experienced by humans	2522
one	2522
the most devastating forms of trauma experienced by humans	2529
the most devastating forms	2529
trauma experienced by humans	2559
trauma	2559
humans	2581
Approximately half of the patients	2589
Approximately half	2589
the patients	2611
complete cord injury	2629
no preservation of voluntary motor or sensory function below the level of injury -LRB- Tator et al. , 1990 -RRB-	2655
no preservation of voluntary motor	2655
no preservation	2655
voluntary motor	2674
sensory function below the level of injury -LRB- Tator et al. , 1990 -RRB-	2693
sensory function	2693
the level of injury -LRB- Tator et al. , 1990 -RRB-	2716
the level	2716
injury -LRB- Tator et al. , 1990 -RRB-	2729
injury	2729
Tator	2737
et al. , 1990	2743
et al.	2743
1990	2751
Development of powerful strategies to treat SCI	2758
Development	2758
powerful strategies	2773
SCI	2802
a major clinical challenge	2815
recent dramatic progress in cellular transplantation , gene therapy and molecular treatment	2852
recent dramatic progress	2852
cellular transplantation , gene therapy and molecular treatment	2880
cellular transplantation	2880
gene therapy	2906
molecular treatment	2923
the optimism	2958
future cures for such injuries	2977
future cures	2977
such injuries	2994
Grill et al. , 1997a , b ; Giehl et al. , 1997 ; Li et al. , 1997 ; Rapalino et al. , 1998 ; Jones et al. , 2001 ; Blits et al. , 2002 ; Schwab , 2002	3009
Grill	3009
et al. , 1997a , b ; Giehl et al. , 1997 ; Li et al. , 1997 ; Rapalino et al. , 1998 ; Jones et al. , 2001 ; Blits et al. , 2002 ; Schwab , 2002	3015
et al. , 1997a , b	3015
et al.	3015
1997a	3023
b	3030
Giehl et al. , 1997	3033
Giehl	3033
et al. , 1997	3039
et al.	3039
1997	3047
Li et al. , 1997	3053
Li	3053
et al. , 1997	3056
et al.	3056
1997	3064
Rapalino et al. , 1998	3070
Rapalino	3070
et al. , 1998	3079
et al.	3079
1998	3087
Jones et al. , 2001	3093
Jones	3093
et al. , 2001	3099
et al.	3099
2001	3107
Blits et al. , 2002	3113
Blits	3113
et al. , 2002	3119
et al.	3119
2002	3127
Schwab , 2002	3133
Schwab	3133
2002	3141
Olfactory ensheathing cells -LRB- OECs -RRB-	3148
Olfactory ensheathing cells	3148
OECs	3177
growing axons	3190
neurons of the nasal cavity	3209
neurons	3209
the nasal cavity	3220
olfactory mucosa to re-enter the olfactory bulb of the brain and form synapses with second-order neurons -LRB- Doucette , 1984 -RRB-	3237
the olfactory bulb of the brain and form synapses	3266
the olfactory bulb	3266
the brain and form synapses	3288
second-order neurons -LRB- Doucette , 1984 -RRB-	3321
second-order neurons	3321
Doucette	3343
1984	3353
Recent studies	3360
implantation of rodent and human OECs	3391
implantation	3391
rodent and human OECs	3407
one of the most promising strategies to promote longdistance regeneration in the injured spinal cord -LRB- Li et al. , 1997 ; Barnett et al. , 2000 ; Kato et al. , 2000 ; Ramon-Cueto et al. , 2000 -RRB-	3443
one	3443
the most promising strategies	3450
longdistance regeneration	3491
the injured spinal cord -LRB- Li et al. , 1997 ; Barnett et al. , 2000 ; Kato et al. , 2000 ; Ramon-Cueto et al. , 2000 -RRB-	3520
the injured spinal cord	3520
Li et al. , 1997 ; Barnett et al. , 2000 ; Kato et al. , 2000 ; Ramon-Cueto et al. , 2000	3545
Li	3545
et al. , 1997 ; Barnett et al. , 2000 ; Kato et al. , 2000 ; Ramon-Cueto et al. , 2000	3548
et al. , 1997	3548
et al.	3548
1997	3556
Barnett et al. , 2000	3562
Barnett	3562
et al. , 2000	3570
et al.	3570
2000	3578
Kato et al. , 2000	3584
Kato	3584
et al. , 2000	3589
et al.	3589
2000	3597
Ramon-Cueto et al. , 2000	3603
Ramon-Cueto	3603
et al. , 2000	3615
et al.	3615
2000	3623
the number of axons that regrow and reconnect	3634
the number	3634
axons that regrow and reconnect	3648
axons	3648
Gudino-Cabrera et al. , 2000	3703
Gudino-Cabrera	3703
et al.	3718
2000	3726
Neurotrophic factors	3733
critical mediators of neuronal survival and nerve fibre outgrowth	3784
critical mediators	3784
neuronal survival and nerve fibre outgrowth	3806
development	3857
The beneficial effects of neurotrophic factors on neuronal protection and repair in the CNS	3870
The beneficial effects	3870
neurotrophic factors on neuronal protection and repair in the CNS	3896
neurotrophic factors	3896
neuronal protection and repair	3920
the CNS	3954
Tuszynski , 1999 ; Jones et al. , 2001	3989
Tuszynski	3989
1999 ; Jones et al.	4000
1999	4000
Jones et al.	4006
Jones	4006
et al.	4012
2001	4020
more than 30 neurotrophic factors	4036
fewer than six of them	4081
fewer than six	4081
them	4099
potential treatments for lesioned spinal cords in the animal model -LRB- Schwab , 2002 -RRB-	4130
potential treatments	4130
lesioned spinal cords in the animal model -LRB- Schwab , 2002 -RRB-	4155
lesioned spinal cords	4155
the animal model -LRB- Schwab , 2002 -RRB-	4180
the animal model	4180
Schwab	4198
2002	4206
Brain-derived neurotrophic factor and neurotrophin-3	4213
Brain-derived neurotrophic factor	4213
neurotrophin-3	4251
they	4312
a role in promoting regeneration of spinal motor pathways -LRB- Jones et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003 -RRB-	4322
a role	4322
regeneration of spinal motor pathways -LRB- Jones et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003 -RRB-	4342
regeneration	4342
spinal motor pathways -LRB- Jones et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003 -RRB-	4358
spinal motor pathways	4358
Jones et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003	4381
Jones	4381
et al. , 2001 ; Liu et al. , 2002 ; Tuszynski et al. , 2003 ; Zhou et al. , 2003	4387
et al. , 2001	4387
et al.	4387
2001	4395
Liu et al. , 2002	4401
Liu	4401
et al. , 2002	4405
et al.	4405
2002	4413
Tuszynski et al. , 2003	4419
Tuszynski	4419
et al. , 2003	4429
et al.	4429
2003	4437
Zhou et al. , 2003	4443
Zhou	4443
et al. , 2003	4448
et al.	4448
2003	4456
Brain-derived neurotrophic factor	4463
rubrospinal tract -LRB- RST -RRB- regeneration	4521
rubrospinal tract -LRB- RST -RRB-	4521
rubrospinal tract	4521
RST	4540
regeneration	4545
limited effects on corticospinal tract -LRB- CST -RRB-	4567
limited effects	4567
corticospinal tract -LRB- CST -RRB-	4586
corticospinal tract	4586
CST	4607
regeneration -LRB- Schnell et al. , 1994 ; Tetzlaff et al. , 1994 -RRB-	4612
regeneration	4612
Schnell	4626
et al. , 1994 ; Tetzlaff et al. , 1994	4634
et al.	4634
1994 ; Tetzlaff et al.	4642
1994	4642
Tetzlaff et al.	4648
Tetzlaff	4648
et al.	4657
1994	4665
Neurotrophin-3 , which has been found to augment the growth of corticospinal axons after spinal cord injury ,	4672
Neurotrophin-3	4672
the growth of corticospinal axons	4720
the growth	4720
corticospinal axons	4734
spinal cord injury	4760
the death of some corticospinal neurons -LRB- Giehl et al. , 2001 -RRB-	4807
the death	4807
some corticospinal neurons -LRB- Giehl et al. , 2001 -RRB-	4820
some corticospinal neurons	4820
Giehl	4848
et al. , 2001	4854
et al.	4854
2001	4862
More recent studies	4869
removal of NT-3 or blocking TrkC activity	4904
removal	4904
NT-3 or blocking TrkC activity	4915
NT-3	4915
TrkC activity	4932
myelination of Schwann cells , which is known to be very important for functional recovery -LRB- Chan et al. , 2001 ; Cosgaya et al. , 2002 -RRB-	4960
myelination	4960
Schwann cells , which is known to be very important for functional recovery -LRB- Chan et al. , 2001 ; Cosgaya et al. , 2002 -RRB-	4975
Schwann cells	4975
functional recovery -LRB- Chan et al. , 2001 ; Cosgaya et al. , 2002 -RRB-	5030
functional recovery	5030
Chan	5051
et al. , 2001 ; Cosgaya et al. , 2002	5056
et al.	5056
2001 ; Cosgaya et al.	5064
2001	5064
Cosgaya et al.	5070
Cosgaya	5070
et al.	5078
2002	5086
The glial cell line-derived neurotrophic factor -LRB- GDNF -RRB- , originally identified as a trophic factor for midbrain dopaminergic neurons -LRB- Lin et al. , 1993 -RRB- ,	5093
The glial cell line-derived neurotrophic factor -LRB- GDNF -RRB-	5093
The glial cell	5093
line-derived neurotrophic factor -LRB- GDNF -RRB-	5108
line-derived neurotrophic factor	5108
GDNF	5142
a trophic factor for midbrain dopaminergic neurons -LRB- Lin et al. , 1993 -RRB-	5174
a trophic factor	5174
midbrain dopaminergic neurons -LRB- Lin et al. , 1993 -RRB-	5195
midbrain dopaminergic neurons	5195
Lin	5226
et al. , 1993	5230
et al.	5230
1993	5238
the most potent trophic factor for motoneurons -LRB- Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995 -RRB-	5266
the most potent trophic factor	5266
motoneurons -LRB- Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995 -RRB-	5301
motoneurons	5301
Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995	5314
Henderson	5314
et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995	5324
et al. , 1994	5324
et al.	5324
1994	5332
Li et al. , 1995	5338
Li	5338
et al. , 1995	5341
et al.	5341
1995	5349
Oppenheim et al. , 1995	5355
Oppenheim	5355
et al. , 1995	5365
et al.	5365
1995	5373
Fibroblasts expressing GDNF	5380
Fibroblasts	5380
GDNF	5403
axon elongation of primary cultured cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5438
axon elongation	5438
primary cultured cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5457
primary	5457
cortical neurons -LRB- Paratcha et al. , 2003 -RRB-	5474
cortical neurons	5474
Paratcha	5492
et al. , 2003	5501
et al.	5501
2003	5509
a similar culture system	5519
cortical neurons growing on a monolayer of fibroblasts expressing brain-derived neurotrophic factor	5545
cortical neurons	5545
a monolayer of fibroblasts	5573
a monolayer	5573
fibroblasts	5588
brain-derived neurotrophic factor	5611
a great number of shorter and more branching neurites	5667
a great number	5667
shorter and more branching neurites	5685
GDNF	5738
a more potent effect in stimulating axonal growth in these cells -LRB- Paratcha et al. , 2003 -RRB-	5752
a more potent effect	5752
axonal growth	5788
these cells -LRB- Paratcha et al. , 2003 -RRB-	5805
these cells	5805
Paratcha	5818
et al. , 2003	5827
et al.	5827
2003	5835
GDNF	5855
motor axon outgrowth across the surrounding white matter in the organotypic spinal cord culture model -LRB- Ho et al. , 2000 -RRB-	5879
motor axon outgrowth	5879
the surrounding white matter in the organotypic spinal cord culture model -LRB- Ho et al. , 2000 -RRB-	5907
the surrounding white matter	5907
the organotypic spinal cord culture model -LRB- Ho et al. , 2000 -RRB-	5939
the organotypic spinal cord culture model	5939
Ho	5982
et al. , 2000	5985
et al.	5985
2000	5993
the spinal cord	6018
GDNF	6035
a trophic effect	6058
corticospinal neurons	6078
longterm survival	6112
axotomy -LRB- Giehl et al. , 1997 -RRB-	6136
axotomy	6136
Giehl	6145
et al. , 1997	6151
et al.	6151
1997	6159
GDNF	6176
behavioural and anatomical neuroprotection following SCI -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	6214
behavioural and anatomical neuroprotection	6214
SCI -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	6267
SCI	6267
Watabe	6272
et al. , 2000 ; Cheng et al. , 2002	6279
et al.	6279
2000 ; Cheng et al.	6287
2000	6287
Cheng et al.	6293
Cheng	6293
et al.	6299
2002	6307
Injections and pumps	6314
neurotrophic factors	6358
the lesion site	6382
these methods	6408
long-term , localized , high-dose neurotrophic factor delivery	6437
An alternative approach that achieves long-term and site-specific delivery of neurotrophic factors to the injured spinal cord	6499
An alternative approach	6499
long-term and site-specific delivery of neurotrophic factors	6537
long-term and site-specific delivery	6537
neurotrophic factors	6577
the injured spinal cord	6601
ex vivo gene therapy -LRB- Tuszynski , 1997 -RRB-	6628
ex vivo gene therapy	6628
Tuszynski	6650
1997	6661
Schwann cells , fibroblasts and intercostal nerve grafts genetically engineered to express neurotrophic factors	6668
Schwann cells , fibroblasts and intercostal nerve grafts	6668
Schwann cells	6668
fibroblasts	6683
intercostal nerve grafts	6699
neurotrophic factors	6758
Grill et al. , 1997 ; Menei et al. , 1998 ; Tuszynski et al. , 1998 ; Blits et al. , 1999 , 2000 ; Liu et al. , 1999a , b ; Blesch et al. , 2001	6799
Grill	6799
et al. , 1997 ; Menei et al. , 1998 ; Tuszynski et al. , 1998 ; Blits et al. , 1999 , 2000 ; Liu et al. , 1999a , b ; Blesch et al. , 2001	6805
et al. , 1997	6805
et al.	6805
1997	6813
Menei et al. , 1998	6819
Menei	6819
et al. , 1998	6825
et al.	6825
1998	6833
Tuszynski et al. , 1998	6839
Tuszynski	6839
et al. , 1998	6849
et al.	6849
1998	6857
Blits et al. , 1999 , 2000	6863
Blits	6863
et al. , 1999 , 2000	6869
et al.	6869
1999	6877
2000	6883
Liu et al. , 1999a , b	6889
Liu	6889
et al. , 1999a , b	6893
et al.	6893
1999a	6901
b	6908
Blesch et al. , 2001	6911
Blesch	6911
et al. , 2001	6918
et al.	6918
2001	6926
These studies	6933
various axonal populations	6980
most cases	7015
the majority of regenerating axons	7027
the majority	7027
regenerating axons	7043
the transplant	7083
few fibres	7102
the site of injury	7133
the site	7133
injury	7145
Implants of OECs	7153
Implants	7153
OECs	7165
neurotrophic factor delivery	7188
this	7223
axons	7260
the distal part of the spinal cord -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	7278
the distal part	7278
the spinal cord -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	7297
the spinal cord	7297
Li	7314
et al. , 1997 ; Ramon-Cueto et al. , 2000	7317
et al.	7317
1997 ; Ramon-Cueto et al.	7325
1997	7325
Ramon-Cueto et al.	7331
Ramon-Cueto	7331
et al.	7343
2000	7351
the use of genetically engineered fibroblasts , which are non-CNS in origin and may become tumorigenic	7382
the use	7382
genetically engineered fibroblasts , which are non-CNS in origin and may become tumorigenic	7393
genetically engineered fibroblasts	7393
origin	7450
The feasibility of transplanting genetically modified OECs into the intact and injured spinal cord	7485
The feasibility	7485
genetically modified OECs	7518
the intact and injured spinal cord	7549
Ruitenberg and colleagues	7613
Ruitenberg et al. , 2002	7640
Ruitenberg	7640
et al.	7651
2002	7659
upgrading of the growth-promoting properties of OEC by having them secrete additional neurotrophic factors	7677
upgrading	7677
the growth-promoting properties of OEC by having them secrete additional neurotrophic factors	7690
the growth-promoting properties	7690
OEC by having them secrete additional neurotrophic factors	7725
OEC	7725
them	7739
additional neurotrophic factors	7752
a valuable strategy for promoting spinal cord repair -LRB- Blits et al. , 2002 ; Ruitenberg et al. , 2002 -RRB- , since limited neurotrophic factor expression of OECs has been reported -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	7791
a valuable strategy	7791
spinal cord repair -LRB- Blits et al. , 2002 ; Ruitenberg et al. , 2002 -RRB-	7825
spinal cord repair	7825
Blits	7845
et al. , 2002 ; Ruitenberg et al. , 2002	7851
et al.	7851
2002 ; Ruitenberg et al.	7859
2002	7859
Ruitenberg et al.	7865
Ruitenberg	7865
et al.	7876
2002	7884
limited neurotrophic factor expression of OECs	7897
limited neurotrophic factor expression	7897
OECs	7939
Boruch	7963
et al. , 2001 ; Woodhall et al. , 2001	7970
et al.	7970
2001 ; Woodhall et al.	7978
2001	7978
Woodhall et al.	7984
Woodhall	7984
et al.	7993
2001	8001
the present study	8011
we	8030
the ability of genetically modi ®	8040
the ability	8040
genetically modi ®	8055
OECs	8075
a high level of GDNF	8091
a high level	8091
GDNF	8107
spinal cord repair	8132
The GDNF gene	8152
OECs using a retroviral system	8186
OECs	8186
a retroviral system	8197
The engineered OECs	8218
® rst characterized by their ability to express and secrete biologically active GDNF in vitro	8243
® rst	8243
their ability to express and secrete biologically active GDNF in vitro	8265
biologically active GDNF	8302
implantation into the spinal cord of adult rats with complete spinal cord transection	8343
implantation	8343
the spinal cord of adult rats with complete spinal cord transection	8361
the spinal cord	8361
adult rats with complete spinal cord transection	8380
adult rats	8380
complete spinal cord transection	8396
OEC survival and GDNF production	8430
OEC survival	8430
GDNF production	8447
The locomotor functions of animals	8478
The locomotor functions	8478
animals	8505
axon regeneration	8532
the morphological level	8567
our knowledge	8595
we	8610
the first time	8624
the genetically modified OECs	8644
GDNF in vivo	8699
GDNF	8699
vivo	8707
recovery	8737
SCI	8752
Materials and methods	8758
Materials	8758
methods	8772
Primary culture and purification of OECs Primary olfactory bulb cultures were set up from adult Sprague ± Dawley rats	8780
Primary culture and purification	8780
OECs	8816
Primary olfactory bulb cultures	8821
adult Sprague ± Dawley rats	8870
2.5 months	8898
The modified protocol of Ramon - Cueto and colleagues -LRB- Ramon-Cueto et al. , 1998 -RRB-	8915
The modified protocol of Ramon - Cueto and colleagues	8915
The modified protocol of Ramon	8915
The modified protocol	8915
Ramon	8940
Cueto and colleagues	8947
Cueto	8947
colleagues	8957
Ramon-Cueto	8969
et al. , 1998	8981
et al.	8981
1998	8989
Brie ¯ y , the olfactory nerve layer was peeled away from the rest of the olfactory bulb , then	9005
Brie	9005
y	9010
the olfactory nerve layer	9013
the rest of the olfactory bulb	9060
the rest	9060
the olfactory bulb	9072
0.25 % trypsin and 0.03 % collagenase	9114
0.25 % trypsin	9114
0.03 % collagenase	9132
0.03 %	9132
collagenase	9138
37 °C for 30 min	9167
37 °C	9167
30 min	9176
The cells	9184
D/F12 ±	9216
10 % fetal bovine serum	9222
uncoated dishes	9273
each for 12 h at 37 °C in 5 % CO2	9296
each	9296
12 h at 37 °C in 5 % CO2	9305
12 h	9305
37 °C in 5 % CO2	9313
37 °C	9313
5 % CO2	9321
The cell suspension	9328
5 µl -LRB- approximately 300 000 cells -RRB-	9366
5 µl	9366
approximately 300 000 cells	9372
100 mm Petri dishes	9415
45 min at 37 °C in 5 % CO2	9439
45 min	9439
37 °C in 5 % CO2	9449
37 °C	9449
5 % CO2	9457
These dishes	9465
anti-rabbit immunoglobulin G antibody	9503
1.5 µg polyclonal rabbit p-75 NGFR antibody -LRB- Santa Cruz Biotechnology -RRB- , for 12 h at 4 °C and then with phosphatebuffered saline -LRB- PBS -RRB- ±	9542
1.5 µg polyclonal rabbit p-75 NGFR antibody -LRB- Santa Cruz Biotechnology -RRB- , for 12 h at 4 °C	9542
1.5 µg polyclonal rabbit p-75 NGFR antibody	9542
1.5 µg	9542
polyclonal rabbit p-75 NGFR antibody	9549
Santa Cruz Biotechnology	9587
12 h at 4 °C	9618
12 h	9618
4 °C	9626
then with phosphatebuffered saline -LRB- PBS -RRB- ±	9634
then	9634
phosphatebuffered saline -LRB- PBS -RRB-	9644
phosphatebuffered saline	9644
PBS	9670
5 %	9675
bovine serum albumin for 4 h	9678
bovine serum albumin	9678
4 h	9703
room temperature	9710
PBS	9728
the dishes	9749
each step	9766
Unbound cells	9777
the attached cells	9811
a cell scraper	9851
poly-L-lysine-treated 25 mm2 ¯ asks , and incubated with D/F12 ± 10 % fetal bovine serum containing as mitogen 2 µM forskolin -LRB- Sigma -RRB- and 20 µg/ml pituitary extract -LRB- Sigma -RRB-	9887
poly-L-lysine-treated 25 mm2 ¯ asks , and incubated with D/F12 ± 10 % fetal bovine serum containing as mitogen 2 µM forskolin -LRB- Sigma -RRB- and 20 µg/ml pituitary extract	9887
25	9909
mm2 ¯	9912
D/F12 ±	9942
10 % fetal bovine serum containing as mitogen 2 µM forskolin -LRB- Sigma -RRB-	9948
10 % fetal bovine serum	9948
mitogen 2 µM forskolin	9985
Sigma	10009
20 µg/ml	10020
Sigma	10048
The purity of the cultured OECs	10056
The purity	10056
the cultured OECs	10070
the	10070
OECs	10083
the number of Hoechst-labelled nuclei	10116
the number	10116
Hoechst-labelled nuclei	10130
the number of p-75 NGFR immunoreactive cells	10159
the number	10159
p-75 NGFR immunoreactive cells	10173
a microscope	10210
Retroviral preparation and infection of OECs The cDNA encoding rat preproGDNF	10224
Retroviral preparation and infection	10224
OECs The cDNA encoding rat preproGDNF	10264
OECs The cDNA	10264
OECs	10264
The cDNA	10269
rat preproGDNF	10287
the RTPCR method	10324
total RNA extracted from rat brain	10346
total RNA	10346
rat brain	10371
Specific primers -LRB- forward , 5 ` - GGAAGCTTATGAAGTTATGGGATGTCG-3 ` ; reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 ` -RRB- for PCR	10382
Specific primers -LRB- forward , 5 ` - GGAAGCTTATGAAGTTATGGGATGTCG-3 ` ; reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 ` -RRB-	10382
Specific primers	10382
forward , 5 ` - GGAAGCTTATGAAGTTATGGGATGTCG-3 ` ; reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 `	10400
forward	10400
5 ` - GGAAGCTTATGAAGTTATGGGATGTCG-3 ` ; reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 `	10409
5	10409
GGAAGCTTATGAAGTTATGGGATGTCG-3	10412
reverse , 5 ` - GAGGATCCTCAGATACATCCACACC-3 `	10444
reverse	10444
5	10453
GAGGATCCTCAGATACATCCACACC-3	10457
PCR	10491
preproGDNF cDNA that yielded 652 bp amplified products	10520
preproGDNF cDNA	10520
652 bp	10549
products	10566
GDNF cDNA	10581
U3 area of the 3 ` long terminal repeat -LRB- LTR -RRB- of the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB- by EcoRV and BamHI enzyme sites -LRB- pN2A-GDNF -RRB-	10609
U3 area	10609
the 3 ` long terminal repeat -LRB- LTR -RRB- of the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB- by EcoRV and BamHI enzyme sites -LRB- pN2A-GDNF -RRB-	10620
the 3 ` long terminal repeat -LRB- LTR -RRB- of the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB- by EcoRV and BamHI enzyme sites	10620
repeat -LRB- LTR -RRB- of the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB- by EcoRV and BamHI enzyme	10641
repeat -LRB- LTR -RRB-	10641
repeat	10641
LTR	10649
the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB- by EcoRV and BamHI enzyme	10657
the replication-defective recombinant retroviral pN2A -LRB- Hantzopoulos et al. , 1989 -RRB-	10657
the replication-defective recombinant retroviral pN2A	10657
Hantzopoulos	10712
et al. , 1989	10725
et al.	10725
1989	10733
EcoRV and BamHI enzyme	10742
pN2A-GDNF	10772
Fig. 1	10796
the unique feature of this double-copy vector	10804
the unique feature	10804
this double-copy vector	10826
gene inserted in the 3 ` - LTR is capable of duplication and transfer to the 5 ` - LTR in infected cells , which can improve the expression of transduced genes	10873
gene	10873
the 3	10890
LTR	10898
duplication and transfer to the 5 `	10916
duplication	10916
transfer	10932
the 5	10944
LTR in infected cells , which can improve the expression of	10951
LTR	10951
infected cells , which can improve the expression of	10958
infected cells	10958
the expression of	10992
the expression	10992
genes	11021
The construct	11028
restriction analysis and sequencing	11059
Lipofectamine -LRB- Gibco -RRB- - packaged pN2A-GDNF was used to transfect the packaging cell line , PA317 -LRB- Miller and Buttimore , 1986 -RRB- .	11096
Lipofectamine -LRB- Gibco -RRB-	11096
Lipofectamine	11096
Gibco	11111
pN2A-GDNF	11127
the packaging cell line , PA317 -LRB- Miller and Buttimore , 1986 -RRB-	11159
the packaging cell line	11159
PA317	11184
Miller and Buttimore	11191
1986	11213
The neomycin analogue G418	11220
resistant colonies	11267
Viral supernatants from these colonies	11287
Viral supernatants	11287
these colonies	11311
NIH 3T3 cells as described previously -LRB- Whittemore et al. , 1994 -RRB-	11341
NIH 3T3 cells	11341
Whittemore	11380
et al. , 1994	11391
et al.	11391
1994	11399
The cell line -LRB- PA317-GDNF2 -RRB- with the highest titre -LRB- 8 3 104 colony-forming units/ml -RRB-	11406
The cell line -LRB- PA317-GDNF2 -RRB-	11406
The cell line	11406
PA317-GDNF2	11421
the highest titre -LRB- 8 3 104 colony-forming units/ml -RRB-	11439
the highest titre	11439
8 3 104 colony-forming units/ml	11458
8	11458
3 104 colony-forming units/ml	11460
3 104	11460
colony-forming units/ml	11466
the purified adult rat	11510
primary OECs	11533
The most effective method for infecting dividing OECs	11547
The most effective method	11547
OECs	11596
a 2 h pretreatment with 8 pg/ml polybrene followed by overnight infection with the recombinant retrovirus in medium containing mitogens	11605
a 2 h pretreatment	11605
8 pg/ml polybrene followed by overnight infection with the recombinant retrovirus in medium containing mitogens	11629
8 pg/ml polybrene	11629
overnight infection	11659
the recombinant retrovirus in medium	11684
the recombinant retrovirus	11684
medium	11714
mitogens	11732
The same procedure	11742
the next day	11774
polybrene	11792
only l	11816
Four	11826
five days	11834
the last infection	11850
the OECs	11870
200 mg/ml G418	11898
the selected population	11919
a stable manner	11956
the cells	11973
the same selection medium , with a maximum total number of passages of six or seven ,	12003
the same selection medium	12003
a maximum total number of passages of six or seven	12035
a maximum total number	12035
passages of six or seven	12061
passages	12061
six or seven	12073
enough OECs	12098
experiments	12114
Characterization of GDNF OECs Primary cultures of adult rat normal OECs and GDNF OECs	12127
Characterization	12127
GDNF OECs Primary cultures	12147
adult rat normal OECs and GDNF OECs	12177
10 min with 4 % paraformaldehyde	12228
10 min	12228
4 % paraformaldehyde	12240
PBS	12278
1 % bovine serum albumin	12300
30 min	12328
the cultures	12336
4 °C	12377
the rabbit polyclonal antihuman GDNF antibody -LRB- 1/200 ; Promega -RRB- , anti-p75NGFR rabbit antibody -LRB- 5 pg/ml , Santa Cruz Biotechnology -RRB- , monoclonal mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1 : 1000 ; Sigma -RRB- and anti- S-100 mouse antibody -LRB- 1 : 2000 ; Sigma -RRB- diluted in PBS containing 1 % bovine serum albumin	12386
the rabbit polyclonal antihuman GDNF antibody -LRB- 1/200 ; Promega -RRB-	12386
the rabbit	12386
polyclonal antihuman GDNF antibody -LRB- 1/200 ; Promega -RRB-	12397
polyclonal antihuman GDNF antibody	12397
1/200 ; Promega	12433
1/200	12433
Promega	12440
anti-p75NGFR rabbit antibody -LRB- 5 pg/ml , Santa Cruz Biotechnology -RRB-	12450
anti-p75NGFR rabbit antibody	12450
5 pg/ml , Santa Cruz Biotechnology	12480
5 pg/ml	12480
Santa Cruz Biotechnology	12489
monoclonal mouse anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1 : 1000 ; Sigma -RRB-	12516
monoclonal mouse	12516
anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1 : 1000 ; Sigma -RRB-	12533
anti-glial fibrillary acidic protein -LRB- GFAP -RRB-	12533
anti-glial fibrillary acidic protein	12533
GFAP	12571
1 : 1000 ; Sigma	12578
1 : 1000	12578
Sigma	12588
anti- S-100 mouse antibody -LRB- 1 : 2000 ; Sigma -RRB- diluted in PBS containing 1 % bovine serum albumin	12599
anti- S-100 mouse antibody -LRB- 1 : 2000 ; Sigma -RRB-	12599
anti- S-100 mouse antibody	12599
1 : 2000 ; Sigma	12627
1 : 2000	12627
Sigma	12637
PBS	12655
1 % bovine serum albumin	12670
The next day	12695
the cultures	12708
PBS	12742
40 min at 37 °C with ¯ uorescein isothiocyanate-labelled secondary antibodies -LRB- Promega -RRB-	12769
40 min	12769
37 °C with ¯ uorescein isothiocyanate-labelled secondary antibodies -LRB- Promega -RRB-	12779
37 °C	12779
¯ uorescein isothiocyanate-labelled secondary antibodies -LRB- Promega -RRB-	12789
¯ uorescein isothiocyanate-labelled secondary antibodies	12789
¯ uorescein	12789
Promega	12846
They	12856
an Olympus BX-50 ¯ uorescence microscope	12896
Assay of GDNF production The amount of GDNF secreted by GDNF OECs	12937
Assay	12937
GDNF production The amount of GDNF secreted by GDNF OECs	12946
GDNF production	12946
The amount of GDNF	12962
The amount	12962
GDNF	12976
GDNF OECs	12993
enzyme-linked immunosorbent assay -LRB- ELISA -RRB-	13019
enzyme-linked immunosorbent assay	13019
ELISA	13054
the GDNF Emax ImmunoAssay System -LRB- Promega -RRB-	13067
the GDNF Emax ImmunoAssay System	13067
Promega	13101
the manufacturer 's instructions	13124
the manufacturer 's	13124
the ELISA plates -LRB- 96 wells -RRB-	13157
the ELISA plates	13157
96 wells	13175
an anti-GDNF monoclonal antibody -LRB- pH 8.2 -RRB-	13202
an anti-GDNF monoclonal antibody	13202
pH 8.2	13236
overnight at 4 ± 8 °C	13244
overnight	13244
4 ± 8 °C	13257
4 ±	13257
8 °C	13259
Plates	13264
1 h at room temperature	13293
1 h	13293
room temperature	13300
buffer	13331
GDNF standards ranging from 0 to 1000 pg/ml	13339
GDNF standards	13339
0	13367
1000 pg/ml	13372
recombinant GDNF	13403
Conditioned medium -LRB- CM -RRB-	13421
Conditioned medium	13421
CM	13441
2 x 106 cells in 2 ml medium	13464
2	13464
106 cells in 2 ml medium	13468
106 cells	13468
2 ml medium	13481
only 1 % fetal bovine serum for 24 h	13503
only 1 % fetal bovine serum	13503
24 h	13534
the wells -LRB- 100 µl -RRB- undiluted or diluted	13554
the wells -LRB- 100 µl -RRB-	13554
the wells	13554
100 µl	13565
1 : 10 or 1 : 100	13594
1 : 10	13594
1 : 100	13604
Samples and standards	13613
room temperature for 6 h on a shaker	13653
room temperature	13653
6 h on a shaker	13674
6 h	13674
a shaker	13681
The plate	13691
chicken anti-human GDNF polyclonal antibody	13738
chicken anti-human GDNF	13738
polyclonal antibody	13762
4 °C , horseradish peroxidase -LRB- HRP -RRB-	13795
4 °C	13795
horseradish peroxidase -LRB- HRP -RRB-	13800
horseradish peroxidase	13800
HRP	13824
antichicken antibody -LRB- 1 : 5000 -RRB-	13840
antichicken antibody	13840
1 : 5000	13862
1	13862
5000	13866
room temperature for 2 h , and the enzyme substrate tetramethylbenzidine for 15 min	13875
room temperature for 2 h	13875
room temperature	13875
2 h	13896
the enzyme substrate tetramethylbenzidine for 15 min	13905
the enzyme substrate tetramethylbenzidine	13905
15 min	13951
room temperature	13961
PBS	13979
the plates	14000
each step	14017
The enzyme reaction	14028
100 ml of 1 M phosphoric acid per well	14070
100 ml	14070
1 M phosphoric acid per well	14080
1 M phosphoric acid	14080
well	14104
the absorbance	14113
450 nm	14144
Sample values	14152
the standard curve in the linear range	14187
the standard curve	14187
the linear range	14209
The biological activity of the secreted GDNF	14227
The biological activity	14227
the secreted GDNF	14254
the	14254
GDNF	14267
a PC12 cell line , which stably expresses GDNF receptor GFRa1 and Ret -LRB- Chen et al. , 2001 -RRB-	14289
a PC12 cell line	14289
GDNF receptor GFRa1 and Ret -LRB- Chen et al. , 2001 -RRB-	14330
GDNF receptor GFRa1	14330
Ret -LRB- Chen et al. , 2001 -RRB-	14354
Ret	14354
Chen	14359
et al. , 2001	14364
et al.	14364
2001	14372
Brie ¯ y , 2 3 104 PC12-GFRa-Ret cells	14379
Brie ¯ y	14379
Brie	14379
y	14384
2 3 104 PC12-GFRa-Ret cells	14387
2 3	14387
104 PC12-GFRa-Ret cells	14391
each well of a 24-well plate -LRB- Costar -RRB- that had been coated with poly-L-lysine	14429
each well	14429
a 24-well plate -LRB- Costar -RRB- that had been coated with poly-L-lysine	14442
a 24-well plate	14442
Costar	14459
poly-L-lysine	14493
attachment	14514
the cells	14526
CM	14552
OECs or GDNF OECs	14560
PBS	14579
negative control	14595
100 ng/ml GDNF	14616
the positive control	14635
GDNF	14657
as previously described -LRB- Chen et al. , 2000 -RRB-	14675
as previously described	14675
as previously	14675
Chen	14700
et al. , 2000	14705
et al.	14705
2000	14713
Five days later	14720
the effect of GDNF on cell differentiation	14737
the effect	14737
GDNF on cell differentiation	14751
GDNF	14751
cell differentiation	14759
Cells possessing one or more neurites of a length more than twice the diameter of the cell body	14796
Cells	14796
one or more neurites of a length	14813
one or more neurites	14813
a length	14837
twice the diameter of the cell body	14856
twice the diameter	14856
the cell body	14878
Each value	14917
the mean ± SEM sampled from three independent experiments	14931
the mean ± SEM	14931
three independent experiments	14959
Hoechst labelling of OECs When cells reached con ¯ uence , monolayers of purified OECs or GDNF OECs	14990
Hoechst labelling	14990
OECs When cells reached con ¯ uence , monolayers of purified OECs or GDNF OECs	15011
OECs	15011
cells	15021
¯ uence , monolayers of purified OECs or GDNF OECs	15038
¯ uence	15038
monolayers of purified OECs or GDNF OECs	15046
monolayers	15046
purified OECs or GDNF OECs	15060
37 °C in 1.5 µg/ml of the nuclear ¯ uorochrome bisbenzimide -LRB- Hoechst 33342 ; Sigma -RRB- for 15 min	15105
37 °C	15105
1.5 µg/ml of the nuclear ¯ uorochrome bisbenzimide -LRB- Hoechst 33342 ; Sigma -RRB- for 15 min	15113
1.5 µg/ml	15113
the nuclear ¯ uorochrome bisbenzimide -LRB- Hoechst 33342 ; Sigma -RRB- for 15 min	15126
the nuclear ¯ uorochrome bisbenzimide -LRB- Hoechst 33342 ; Sigma -RRB-	15126
the nuclear ¯ uorochrome bisbenzimide	15126
Hoechst 33342 ; Sigma	15164
Hoechst 33342	15164
Sigma	15179
15 min	15190
several washes in Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	15204
several washes	15204
Dulbecco 's modified Eagle medium -LRB- DMEM -RRB-	15222
Dulbecco 's modified Eagle medium	15222
Dulbecco 's	15222
DMEM	15256
cells	15263
transplantation	15304
Surgical procedures Animal care and use	15321
Surgical procedures	15321
Animal care and use	15341
recommended NIH guidelines	15370
Female adult Sprague ± Dawley rats	15398
2 % pentobarbital sodium -LRB- 0.2 ml/kg -RRB-	15455
2 % pentobarbital sodium	15455
0.2 ml/kg	15480
Laminectomy	15510
the dorsal surface of the T8 ± 9 segment , followed by a transection at T8 using microscissors	15546
the dorsal surface	15546
the T8 ± 9 segment , followed by a transection at T8 using microscissors	15568
the T8 ± 9 segment	15568
a transection at T8	15598
a transection	15598
T8	15615
microscissors	15624
The distal stump	15639
veri	15690
cation of complete transection	15695
cation	15695
complete transection	15705
Rats	15727
stereotaxic injections	15746
four sites of the midline of both cord stumps -LRB- ventral funiculus , grey commissure , dorsal CST , gracile fasciculus -RRB- at 1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB- using sterile glass needles	15774
four sites	15774
the midline of both cord stumps -LRB- ventral funiculus , grey commissure , dorsal CST , gracile fasciculus -RRB- at 1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB- using sterile glass needles	15788
the midline	15788
both cord stumps -LRB- ventral funiculus , grey commissure , dorsal CST , gracile fasciculus -RRB- at 1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15803
cord stumps -LRB- ventral funiculus , grey commissure , dorsal CST , gracile fasciculus -RRB- at 1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15808
cord stumps -LRB- ventral funiculus , grey commissure , dorsal CST , gracile fasciculus -RRB-	15808
cord stumps	15808
ventral funiculus , grey commissure , dorsal CST , gracile fasciculus	15821
ventral funiculus	15821
grey commissure	15840
dorsal CST	15857
gracile fasciculus	15869
1 mm from the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15892
1 mm	15892
the transaction site -LRB- Ramon-Cueto et al. , 1998 -RRB-	15902
the transaction site	15902
Ramon-Cueto	15924
et al. , 1998	15936
et al.	15936
1998	15944
sterile glass needles	15956
total	15982
41 animals	15989
eight animals	16019
a transection	16042
no grafted OECs	16061
each site	16082
0.5 µl DMEM	16101
15	16119
a graft of normal OECs , each site receiving 0.5 µl OEC suspension containing about 50 000 cells	16131
a graft	16131
normal OECs , each site receiving 0.5 µl OEC suspension containing about 50 000 cells	16142
normal OECs	16142
each site receiving 0.5 µl OEC suspension containing about 50 000 cells	16155
each site	16155
0.5 µl OEC suspension	16175
50 000 cells	16214
18	16238
a graft of GDNF OECs , each site receiving 0.5 µl cell suspension containing about 50 000 cells	16250
a graft	16250
GDNF OECs , each site receiving 0.5 µl cell suspension containing about 50 000 cells	16261
GDNF OECs	16261
each site receiving 0.5 µl cell suspension containing about 50 000 cells	16272
each site	16272
0.5 µl cell suspension	16292
50 000 cells	16332
rats	16363
22 ±	16381
25 °C on highly absorbent bedding , injected with cefazolin sodium -LRB- 40 mg/day -RRB- for up to 1 week ,	16384
25 °C	16384
highly absorbent bedding , injected with cefazolin sodium -LRB- 40 mg/day -RRB- for up to 1 week ,	16392
highly absorbent bedding	16392
cefazolin sodium -LRB- 40 mg/day -RRB- for up to 1	16432
cefazolin sodium -LRB- 40 mg/day -RRB-	16432
cefazolin sodium	16432
40 mg/day	16450
up to 1	16465
week	16473
bladder expression	16492
normal function	16529
RT-PCR analysis Two months after cell transplantation , animals of the OEC or GDNF OEC group were euthanized with a lethal dose of pentobarbital sodium and T7 ± 9 spinal cord tissue	16555
RT-PCR analysis	16555
Two months	16571
cell transplantation , animals of the OEC or GDNF OEC group	16588
cell transplantation	16588
animals of the OEC or GDNF OEC group	16610
animals	16610
the OEC or GDNF OEC group	16621
a lethal dose of pentobarbital sodium and T7 ± 9 spinal cord tissue	16668
a lethal dose of pentobarbital sodium	16668
a lethal dose	16668
pentobarbital sodium	16685
T7 ± 9 spinal cord tissue	16710
T7	16710
± 9 spinal cord tissue	16712
Total RNA	16749
the tissue using TRIzol -LRB- Gibco BRL -RRB-	16777
the tissue	16777
TRIzol -LRB- Gibco BRL -RRB-	16794
TRIzol	16794
Gibco BRL	16802
the RNA concentration	16817
RNA extraction	16875
the samples	16891
RNase-free DNase	16922
I	16939
cDNA	16946
a Dmniscript TM PT kit -LRB- Qiagen -RRB-	16973
a Dmniscript TM PT kit	16973
Qiagen	16997
PCR	17010
specific primers -LRB- forward , 5 ` - AATATGCCCGAAGATTATCC-3 ` ; reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 ` -RRB-	17015
specific primers	17015
forward , 5 ` - AATATGCCCGAAGATTATCC-3 ` ; reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17033
forward	17033
5 ` - AATATGCCCGAAGATTATCC-3 ` ; reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17042
5	17042
AATATGCCCGAAGATTATCC-3	17045
reverse , 5 ` - GTTTAGCGGAATGCTTTCTT-3 `	17070
reverse	17070
5	17079
GTTTAGCGGAATGCTTTCTT-3	17082
GDNF cDNA to yield 466 bp amplified products	17132
466 bp	17151
products	17168
the RT-PCR , b-actin -LRB- primers : forward , 5-AAGATTTGGCACCACACTTTCTAC - 3 ` ;	17190
the RT-PCR	17190
b-actin -LRB- primers : forward , 5-AAGATTTGGCACCACACTTTCTAC - 3 ` ;	17202
b-actin	17202
primers : forward , 5-AAGATTTGGCACCACACTTTCTAC - 3 `	17211
primers : forward , 5-AAGATTTGGCACCACACTTTCTAC -	17211
primers	17211
5-AAGATTTGGCACCACACTTTCTAC	17229
reverse	17261
5 ` - CACGGTTGGCCTTAGGGTT - 3 ` -RRB-	17270
5	17270
- CACGGTTGGCCTTAGGGTT - 3 `	17272
3	17294
GDNF	17320
Forty picomoles of each primer and 1 mg DNA	17326
Forty picomoles	17326
each primer and 1 mg DNA	17345
each primer	17345
1 mg DNA	17361
PCR , which was carried out in a programmable heating block using cycles consisting of denaturation at 95 °C for 1 min followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17384
PCR	17384
a programmable heating block using cycles consisting of denaturation at 95 °C for 1 min followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17414
a programmable heating block	17414
cycles consisting of denaturation at 95 °C for 1 min followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17449
cycles	17449
denaturation	17470
95 °C for 1 min followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17486
95 °C	17486
1 min followed by annealing at 55 °C for 1 min and DNA extension at 72 °C for 1 min	17495
1 min	17495
annealing	17513
55 °C for 1 min and DNA extension	17526
55 °C	17526
1 min and DNA extension	17535
1 min	17535
DNA extension	17545
72 °C for 1 min	17562
72 °C	17562
1 min	17571
30 cycles of PCR	17584
30 cycles	17584
PCR	17597
samples	17602
1.5 % agarose gel	17634
1.5 %	17634
agarose gel	17639
Gels	17652
ethidium bromide	17675
ultraviolet light	17715
Retrograde tracing with HRP Twelve animals -LRB- three controls , four from the OEC and six from the GDNF OEC group -RRB-	17734
Retrograde tracing with HRP Twelve animals	17734
Retrograde	17734
HRP Twelve animals	17758
three controls , four from the OEC and six from the GDNF OEC group	17778
three controls , four from the OEC	17778
three controls	17778
four from the OEC	17794
four	17794
the OEC	17804
six from the GDNF OEC group	17816
six	17816
the GDNF OEC group	17825
HRP retrograde	17859
Eight weeks	17883
surgery	17901
an aqueous suspension of 30 % HRP -LRB- Sigma ; RZ > 3.0 -RRB- and 2 % dimethyl sulphoxide -LRB- Sigma -RRB-	17910
an aqueous suspension of 30 % HRP -LRB- Sigma ; RZ > 3.0 -RRB-	17910
an aqueous suspension	17910
30 % HRP -LRB- Sigma ; RZ > 3.0 -RRB-	17935
30 % HRP	17935
Sigma ; RZ > 3.0	17944
Sigma	17944
RZ > 3.0	17951
RZ >	17951
RZ	17951
3.0	17955
2 % dimethyl sulphoxide -LRB- Sigma -RRB-	17964
2 % dimethyl sulphoxide	17964
Sigma	17988
bilaterally three or four segments caudal to the transplant	18008
bilaterally three or four segments	18008
three or four	18020
the transplant	18053
diffusion of HRP	18077
diffusion	18077
HRP	18090
the transplant	18099
injection	18121
the surgical exposure	18132
the animals	18169
36 h	18201
1 % paraformaldehyde and 1.25 % glutaraldehyde	18240
1 % paraformaldehyde	18240
1.25 % glutaraldehyde	18264
The brain and spinal cord	18286
The brain	18286
spinal cord	18300
20 % sucrose in 0.1 M PBS at 4 °C overnight	18339
20 % sucrose	18339
0.1 M PBS at 4 °C overnight	18354
0.1 M PBS	18354
4 °C overnight	18367
4 °C	18367
the sensory motor cortex in the forebrain and the magnocellular portion of the red nucleus in the midbrain	18387
the sensory motor cortex	18387
the forebrain and the magnocellular portion of the red nucleus in the midbrain	18415
the forebrain	18415
the magnocellular portion of the red nucleus in the midbrain	18433
the magnocellular portion	18433
the red nucleus in the midbrain	18462
the red nucleus	18462
the midbrain	18481
30 µm	18532
Every third section in the red nucleus or cortex	18539
Every third section	18539
the red nucleus or cortex	18562
tetramethylbenzidine -LRB- Sigma -RRB- and hydrogen peroxide	18619
tetramethylbenzidine -LRB- Sigma -RRB-	18619
tetramethylbenzidine	18619
Sigma	18641
hydrogen peroxide	18652
the method of Mesulam -LRB- Mesulam , 1978 -RRB-	18683
the method	18683
Mesulam -LRB- Mesulam , 1978 -RRB-	18697
Mesulam	18697
Mesulam	18706
1978	18715
neutral red	18749
the sections	18762
a light microscope	18795
The distal spinal cord including the transected area	18815
The distal spinal cord	18815
the transected area	18848
the injection	18907
con ® ned	18925
con ®	18925
there	18942
no spread of dye to the transplant	18952
no spread	18952
the transplant	18972
Animals that did not measure up to this criterion	18988
Animals	18988
this criterion	19023
the study	19059
identification of neurons in the red nucleus and cortex	19074
identification	19074
neurons in the red nucleus and cortex	19092
neurons	19092
the red nucleus and cortex	19103
the caudalmost section through the nucleus magnocellularis and sensory motor cortex where HRP-labelled neurons could be observed	19131
the caudalmost section	19131
the nucleus magnocellularis and sensory motor cortex where HRP-labelled neurons could be observed	19162
the nucleus magnocellularis and sensory motor cortex	19162
HRP-labelled neurons	19221
the first section for analysis	19278
the first section	19278
analysis	19300
The numbers of HRPlabelled and neutral red-labelled rubrospinal neurons -LRB- RSNs -RRB- and corticospinal neurons -LRB- CSNs -RRB- on both sites	19310
The numbers	19310
HRPlabelled and neutral red-labelled rubrospinal neurons -LRB- RSNs -RRB- and corticospinal neurons -LRB- CSNs -RRB-	19325
HRPlabelled and neutral red-labelled rubrospinal neurons	19325
RSNs	19383
corticospinal neurons	19393
CSNs	19416
both sites	19425
a digitizing tablet and PC-based software -LRB- Metamorph -RRB-	19466
a digitizing tablet	19466
PC-based software -LRB- Metamorph -RRB-	19490
PC-based software	19490
Metamorph	19509
The criterion for a CSN	19521
The criterion	19521
a CSN	19539
an HRP-filled pyramidal shape >	19549
an HRP-filled pyramidal shape	19549
4 mm	19580
diameter	19588
the RSN	19602
only neurons with a clearly visible nucleus	19611
only neurons	19611
a clearly visible nucleus	19629
Antegrade tracing with biotinylated dextran amine Antegrade tracing of CST fibres from the motor cortex	19669
Antegrade	19669
dextran amine Antegrade tracing of CST fibres from the motor cortex	19705
dextran amine Antegrade	19705
CST fibres	19740
the motor cortex	19756
Ramon-Cueto et al. -LRB- 2000 -RRB-	19797
Ramon-Cueto et al.	19797
Ramon-Cueto	19797
et al.	19809
2000	19817
Brie ¯ y , animals were anesthetized and two holes	19824
Brie	19824
y	19829
animals	19832
anesthetized and two holes	19845
anesthetized	19845
two holes	19862
the cranium	19888
both sensorimotor cortices	19910
A 10 % solution of biotinylated dextran amine -LRB- BDA ; molecular weight 10 000 ; Molecular Probes -RRB-	19938
A 10 % solution	19938
dextran amine -LRB- BDA ; molecular weight 10 000 ; Molecular Probes -RRB-	19969
dextran amine	19969
BDA ; molecular weight 10 000 ; Molecular Probes	19984
BDA	19984
molecular weight 10 000 ; Molecular Probes	19989
molecular weight 10 000	19989
molecular weight	19989
10 000	20006
Molecular Probes	20014
eight sites of each sensorimotor cortex -LRB- 0.5 ml/site -RRB-	20060
eight sites	20060
each sensorimotor cortex -LRB- 0.5 ml/site -RRB-	20075
each sensorimotor cortex	20075
0.5 ml/site	20101
the entire hindlimb region	20123
Eighteen days	20151
rats	20172
spinal sections	20193
¯ uoresceinconjugated streptavidin	20229
BDA-containing corticospinal axons	20276
CST fibres	20324
we	20335
a method described previously -LRB- Blits et al. , 2000 -RRB-	20347
a method described previously	20347
a method	20347
Blits	20378
et al. , 2000	20384
et al.	20384
2000	20392
the number of CST fibres	20411
the number	20411
CST fibres	20425
the animals that survived for 8 weeks	20439
the animals	20439
8 weeks	20469
the centre of each lesion -LRB- between the proximal and distal scar -RRB-	20478
the centre	20478
each lesion -LRB- between the proximal and distal scar -RRB-	20492
each lesion	20492
the proximal and distal scar	20513
point 0	20592
this point	20606
fibre counting	20618
the sagittal sections and at 2.5 and 4.5 mm proximal and distal	20650
the sagittal sections	20650
at 2.5 and 4.5 mm proximal and distal	20676
at 2.5 and 4.5 mm	20676
the centre of the lesion	20717
the centre	20717
the lesion	20731
Immunohistochemistry Rats	20743
4 % paraformaldehyde in 0.1 M ice-cold phosphate buffer	20788
4 % paraformaldehyde	20788
0.1 M ice-cold phosphate buffer	20811
The spinal cord	20844
5 h	20887
30 % sucrose/PBS	20905
30 mm	20938
sagittal cryosections	20944
Hoechst-labelled OECs	20967
a ¯ uorescent microscope equipped with a 365 nm excitation filter and a 420 nm emission filter	21010
a ¯ uorescent microscope	21010
a 365 nm excitation filter and a 420 nm emission filter	21048
a 365 nm excitation filter	21048
a 420 nm emission filter	21079
immuno ¯ uorescence	21109
sections	21128
0.3 % Triton X-100 / 10 % normal goat serum in 0.1 M PBS	21173
0.3 % Triton X-100	21173
10 % normal goat serum in 0.1 M PBS	21191
10 %	21191
normal goat serum in 0.1 M PBS	21195
normal goat serum	21195
0.1 M PBS	21216
15 min	21230
Primary antibodies	21238
the sections	21278
4 °C	21304
Each section	21309
mouse monoclonal immunoglobulin G	21347
neurofilaments -LRB- Sigma ; 1 : 200 -RRB- and anti-p75NGFR	21389
neurofilaments -LRB- Sigma ; 1 : 200 -RRB-	21389
neurofilaments	21389
Sigma ; 1 : 200	21405
Sigma	21405
1 : 200	21412
anti-p75NGFR	21425
The following day	21439
sections	21458
¯ uorescein isothiocyanateconjugated goat anti-mouse and rhodamine-conjugated goat antirabbit -LRB- Promega -RRB- secondary antibodies	21487
¯ uorescein	21487
goat anti-mouse and rhodamine-conjugated goat antirabbit -LRB- Promega -RRB-	21523
goat anti-mouse and rhodamine-conjugated goat antirabbit	21523
Promega	21581
secondary antibodies	21590
Slides	21612
Olympus	21657
uorescent microscopy	21666
Neurofilament	21688
NF	21703
immunohistostaining	21707
3 mm wide strips of spinal tissue	21760
3 mm wide strips	21760
spinal tissue	21780
the lesion centre	21802
Slides	21821
an Olympus photo microscope -LRB- BX70 -RRB-	21862
an Olympus photo microscope	21862
BX70	21891
The photographs	21898
a video image analysis system -LRB- Metamorph -RRB- in conjunction	21934
a video image analysis system -LRB- Metamorph -RRB-	21934
a video image analysis system	21934
Metamorph	21965
conjunction	21979
a computer	21996
background correction	22014
the grey levels of each slide	22037
the grey levels	22037
each slide	22056
the mean of grey levels for all slides from each animal	22101
the mean	22101
grey levels for all slides from each animal	22113
grey levels	22113
all slides from each animal	22129
all slides	22129
each animal	22145
statistical analysis	22175
Functional recovery Functional tests	22211
operation and 2 h , 3 days and 1 , 2 , 3 , 4 , 5 , 6 , 7 and 8 weeks	22270
operation	22270
2 h	22284
3 days	22289
1 , 2 , 3 , 4 , 5 , 6 , 7 and 8 weeks	22300
1	22300
2	22303
3	22306
4	22309
5	22312
6	22315
7	22318
8 weeks	22324
operation	22338
Locomotor activity	22349
the open-field walking scoring system	22388
One animal at a time	22427
One animal	22427
a time	22441
a circular plastic tray -LRB- 90 cm diameter , 24 cm wall height -RRB- for 5 min	22482
a circular plastic tray -LRB- 90 cm diameter , 24 cm wall height -RRB-	22482
a circular plastic tray	22482
90 cm diameter , 24 cm wall height	22507
90 cm diameter	22507
24 cm wall height	22523
5 min	22546
Behavioural recovery	22553
the BBB -LRB- Basso , Beattie , Bresnahan -RRB- scale -LRB- Basso et al. , 1996 -RRB- , which is composed of 21 different criteria of the movement of the hind limb from complete paralysis to complete mobility	22598
the BBB -LRB- Basso , Beattie , Bresnahan -RRB- scale -LRB- Basso et al. , 1996 -RRB-	22598
the BBB -LRB- Basso , Beattie , Bresnahan -RRB- scale	22598
Basso	22607
Beattie	22614
Bresnahan	22623
Basso	22641
et al. , 1996	22647
et al.	22647
1996	22655
21 different criteria of the movement of the hind limb	22683
21 different criteria	22683
the movement of the hind limb	22708
the movement	22708
the hind limb	22724
complete paralysis	22743
mobility	22774
a second test for hind limb function	22787
a second test	22787
hind limb function	22805
animals	22825
an inclined plane test -LRB- Rivlin and Tator , 1977 -RRB-	22851
an inclined plane test	22851
Rivlin and Tator , 1977	22875
Rivlin	22875
Tator , 1977	22886
Tator	22886
1977	22893
The maximum angle at which the animal could maintain a stable position for 5 s on the inclined plane	22900
The maximum angle	22900
the animal	22927
a stable position	22953
5 s on the inclined plane	22975
5 s	22975
the inclined plane	22982
each evaluation	23022
we	23039
the rats for perineal infection , wounds in the hind limbs , and tail and foot autophagia	23061
the rats for perineal infection	23061
the rats	23061
perineal infection	23074
wounds in the hind limbs	23094
wounds	23094
the hind limbs	23104
tail and foot autophagia	23124
Results	23151
1 Structure of double-copy retroviral vector pN2A-GDNF	23164
1 Structure	23164
double-copy retroviral vector pN2A-GDNF	23179
The original Moloney murine leukaemia virus-based retroviral vector pN2A	23220
The original Moloney murine leukaemia	23220
virus-based retroviral vector pN2A	23258
a GDNF gene in the U3 region of the 3 ` - LTR	23302
a GDNF gene in the U3 region of the 3 `	23302
a GDNF gene	23302
the U3 region of the 3 `	23317
the	23317
region	23324
the 3	23334
LTR	23342
` neo '	23347
a G418/neomycin resistant gene	23356
a G418/neomycin	23356
` Double copy '	23388
the infected cell the transduced gene could be duplicated	23420
the infected cell	23420
the transduced gene	23438
the 5 ` - LTR -LRB- asterisk -RRB-	23497
the 5	23497
- LTR	23503
asterisk	23509
Placement of the foreign gene outside the retroviral transcriptional unit	23520
Placement	23520
the foreign gene outside the retroviral transcriptional unit	23533
the foreign gene	23533
the retroviral transcriptional unit	23558
the negative effects of the retroviral transcriptional unit	23628
the negative effects	23628
the retroviral transcriptional unit	23652
the expression of the foreign gene -LRB- Hantzopoulos et al. , 1989 -RRB-	23709
the expression	23709
the foreign gene -LRB- Hantzopoulos et al. , 1989 -RRB-	23727
the foreign gene	23727
Hantzopoulos	23745
et al. , 1989	23758
et al.	23758
1989	23766
Fig. 2 Characterization of a GDNF-overexpressing OECs cell line .	23774
Fig.	23774
2 Characterization of a GDNF-overexpressing OECs cell line	23779
2 Characterization	23779
a GDNF-overexpressing OECs cell line	23801
-LRB- A -RRB- Phases of GDNF OECs in primary cultures .	23839
-LRB- A -RRB-	23839
Phases of GDNF OECs in primary cultures	23843
Phases	23843
GDNF OECs in primary cultures	23853
GDNF OECs	23853
primary cultures	23866
-LRB- B -RRB- GDNF OECs double-stained with S-100 and Hoechst .	23884
-LRB- B -RRB-	23884
GDNF OECs double-stained with S-100 and Hoechst	23888
GDNF OECs	23888
S-100 and Hoechst	23918
S-100	23918
Hoechst	23928
C , D -RRB- GDNF	23938
OECs	23949
immunostaining for p75NGFR	23988
immunostaining	23988
p75NGFR	24007
GFAP	24039
A small number of GFAP-positive cells that did not express p75NGFR	24045
A small number	24045
GFAP-positive cells that did not express p75NGFR	24063
GFAP-positive cells	24063
p75NGFR	24104
astrocytes -LRB- arrow in C -RRB-	24126
astrocytes	24126
arrow in C	24138
arrow	24138
C	24147
GFAP expression	24151
astrocytes	24188
OECs	24207
Immunostaining for GDNF	24213
Immunostaining	24213
GDNF	24232
GDNF OECs -LRB- E -RRB-	24258
GDNF OECs	24258
E	24269
normal OECs -LRB- F -RRB-	24280
normal OECs	24280
F	24293
Scale	24297
100 µm	24309
This figure	24317
colour	24346
supplementary material	24356
Brain Online	24382
Fig. 3 Detection of ex vivo GDNF secretion from normal OECs and GDNF OECs by ELISA .	24397
Fig. 3 Detection	24397
ex vivo GDNF secretion from normal OECs and GDNF OECs	24417
ex vivo GDNF secretion	24417
normal OECs and GDNF OECs	24445
ELISA	24474
-LRB- A -RRB- GDNF standard curve	24481
-LRB- A -RRB-	24481
GDNF standard curve	24485
the GDNF Emax ImmunoAssay System	24520
-LRB- B -RRB- Bar graph comparing ex vivo GDNF secretion between normal OECs and GDNF OEC groups .	24554
-LRB- B -RRB- Bar graph	24554
-LRB- B -RRB-	24554
Bar graph	24558
ex vivo GDNF secretion between normal OECs and GDNF OEC groups	24578
ex vivo GDNF secretion	24578
normal OECs and GDNF OEC groups	24609
GDNF production by control uninfected OECs	24642
GDNF production	24642
control uninfected OECs	24661
95 pg/ml per 106 cells	24689
95 pg/ml	24689
106 cells	24702
GDNF OECs	24721
an average of 25 ng GDNF/106 cells/24	24740
an average	24740
25 ng GDNF/106 cells/24	24754
P <	24782
0.01 versus normal OEC group	24786
0.01	24786
normal OEC group	24798
Fig. 4 Bar graph comparing differentiation ratios of PC12-GFRa1 - Ret cells among groups .	24817
Fig. 4 Bar graph comparing differentiation ratios of PC12-GFRa1	24817
Fig. 4 Bar graph	24817
differentiation ratios of PC12-GFRa1	24844
differentiation ratios	24844
PC12-GFRa1	24870
Ret cells among groups	24882
Ret cells	24882
groups	24898
PC12-GFRa1-Ret cells	24906
5 days	24946
DMEM -LRB- control -RRB- , GDNF 50 ng/ml , CM obtained from GDNF OECs or uninfected OECs	24958
DMEM	24958
control	24964
GDNF 50 ng/ml	24974
CM obtained from GDNF OECs or uninfected OECs	24989
CM	24989
GDNF OECs or uninfected OECs	25006
GDNF OECs	25006
uninfected OECs	25019
P <	25037
P	25037
<	25039
0.05	25041
control group	25053
ΔΔP < 0.01 versus OEC supernatant	25068
ΔΔP	25068
0.01	25074
OEC supernatant	25086
Fig. 5 Expression of GDNF mRNA transcripts	25104
Fig. 5 Expression	25104
GDNF mRNA transcripts	25125
8 weeks	25160
operation	25174
RT-PCR analysis	25187
Lane A , GDNF OEC group ; lane B , OEC group ; lane C , marker .	25204
Lane A , GDNF OEC group	25204
Lane A	25204
GDNF OEC group	25212
lane B , OEC group	25228
lane B	25228
OEC group	25236
lane C , marker	25247
lane C	25247
marker	25255
The upper GDNF band	25263
460 bp	25293
the control actin band	25304
100 bp	25337
rats injected with GDNF OECs	25348
rats	25348
GDNF OECs	25367
expression of GDNF mRNA in the spinal cord	25378
expression	25378
GDNF mRNA in the spinal cord	25392
GDNF mRNA	25392
the spinal cord	25405
Fig. 6 Transgenetic gene expression of OEC implants in vivo .	25450
Fig.	25450
6 Transgenetic gene expression of OEC implants in vivo	25455
6 Transgenetic gene expression	25455
OEC implants in vivo	25489
OEC implants	25489
vivo	25505
The OECs	25511
the recombinant retrovirus containing GFP	25539
the recombinant retrovirus	25539
GFP	25577
the lesion of the spinal cord	25598
the lesion	25598
the spinal cord	25612
-LRB- A -RRB- The lesion gap	25629
-LRB- A -RRB-	25629
The lesion gap	25633
an intensively GFAP-positive -LRB- red -RRB- border of reactive astrocytes	25665
an intensively GFAP-positive -LRB- red -RRB- border	25665
reactive astrocytes	25710
-LRB- B -RRB- Persistent expression of GFP -LRB- green -RRB-	25731
-LRB- B -RRB- Persistent expression of GFP	25731
-LRB- B -RRB- Persistent expression	25731
B	25732
GFP	25760
OECs	25784
at least 2 months	25795
implantation	25819
determined by native GFP ¯ uorescence	25836
native GFP ¯	25850
Inset	25874
the magnified image	25886
Most GFP-positive OECs	25911
p75 NGFR -LRB- blue -RRB-	25957
p75 NGFR	25957
blue	25967
Additional p75NGFR staining outside the confines of GFP labelling	25974
Additional p75NGFR staining	25974
the confines of GFP labelling	26010
the confines	26010
GFP labelling	26026
the Schwann cells that have invaded the spinal cord , as suggested by Ruitenberg et al. -LRB- 2002 -RRB-	26056
the Schwann cells	26056
the spinal cord	26092
Ruitenberg	26125
et al.	26136
2002	26144
Scale	26151
150 µm	26163
This figure	26171
colour	26200
supplementary material	26210
Brain Online	26236
Fig. 7 NF immunostaining through the spinal cord lesion 8 weeks after injury .	26251
Fig. 7 NF immunostaining	26251
the spinal cord lesion 8 weeks	26284
the spinal cord lesion	26284
8 weeks	26307
injury	26321
-LRB- A -RRB- Haematoxylin and eosin staining	26329
-LRB- A -RRB-	26329
Haematoxylin and eosin staining	26333
spinal cord transection	26383
an obvious traverse scar at the T8 lesion epicentres -LRB- arrow -RRB- and neuronal necrosis , reactive gliosis and cavitation	26419
an obvious traverse scar	26419
the T8 lesion epicentres -LRB- arrow -RRB- and neuronal necrosis , reactive gliosis and cavitation	26447
the T8 lesion epicentres -LRB- arrow -RRB-	26447
the T8	26447
lesion epicentres -LRB- arrow -RRB-	26454
lesion epicentres	26454
arrow	26473
neuronal necrosis , reactive gliosis and cavitation	26484
neuronal necrosis	26484
reactive gliosis	26503
cavitation	26524
adjacent rostral and caudal regions	26538
-LRB- B -RRB- GFAP immunochemistry	26575
-LRB- B -RRB-	26575
GFAP immunochemistry	26579
glial scar -LRB- arrow -RRB- in spinal cord lesion	26606
glial scar -LRB- arrow -RRB-	26606
glial scar	26606
arrow	26618
spinal cord lesion	26628
C , D	26649
C	26649
D	26652
control animals	26658
NF immuno ¯ uorescence at the lesion site -LRB- outlined in C -RRB-	26675
NF immuno ¯ uorescence	26675
the lesion site -LRB- outlined in C -RRB-	26699
the lesion site	26699
C	26728
mostly scattered profiles , and many NFimmunoreactive fibres were stopped at the host ± scar interface -LRB- arrows -RRB-	26741
mostly scattered profiles	26741
many NFimmunoreactive fibres were stopped at the host ± scar interface -LRB- arrows -RRB-	26772
many NFimmunoreactive fibres were stopped at the host ± scar interface	26772
many NFimmunoreactive fibres	26772
the host ± scar interface	26817
arrows	26842
E , F	26852
E	26852
F	26855
the normal OEC group	26861
NF-positive axons -LRB- arrows -RRB-	26893
NF-positive axons	26893
arrows	26912
the lesion -LRB- outlined in E -RRB-	26944
the lesion	26944
E	26968
G , H	26973
G	26973
H	26976
the GDNF OEC group	26982
a dramatically increased amount of NFpositive fibres -LRB- arrows -RRB-	27002
a dramatically increased amount	27002
NFpositive fibres -LRB- arrows -RRB-	27037
NFpositive fibres	27037
arrows	27056
the lesion site -LRB- outlined in G -RRB- ; some of them	27077
the lesion site -LRB- outlined in G -RRB-	27077
the lesion site	27077
G	27106
some of them	27110
some	27110
them	27118
the invaded dorsal root -LRB- asterisk -RRB-	27141
the invaded dorsal root	27141
asterisk	27166
The axonal profiles within the centre of the lesion site	27177
The axonal profiles	27177
the centre of the lesion site	27204
the centre	27204
the lesion site	27218
a variety of orientations	27238
a variety	27238
orientations	27251
Scale bars	27265
100 µm in A , C , E , G ; 25 µm in B , D , F , H	27278
100 µm in A , C , E , G	27278
100 µm	27278
A , C , E , G	27288
25 µm in B , D , F , H	27300
25 µm	27300
B , D , F , H	27309
This figure	27321
colour	27350
supplementary material	27360
Brain Online	27386
Fig. 8 High-magnification microscope images of NF-positive axons sprouting through the lesion centre .	27401
Fig. 8 High-magnification microscope images of NF-positive axons	27401
Fig.	27401
8 High-magnification microscope images of NF-positive axons	27406
8 High-magnification microscope images	27406
NF-positive axons	27448
the lesion centre	27484
-LRB- A -RRB- Normal OEC group .	27503
-LRB- A -RRB-	27503
Normal OEC group	27507
-LRB- B -RRB- GDNF OEC group .	27525
-LRB- B -RRB-	27525
GDNF OEC group	27529
OECs	27555
Hoechst -LRB- blue -RRB- / p75NGFR -LRB- red -RRB- labelling	27577
Hoechst -LRB- blue -RRB-	27577
Hoechst	27577
p75NGFR -LRB- red -RRB-	27592
p75NGFR	27592
red	27601
numerous NF-positive axons -LRB- green -RRB- growing through the injury site 8 weeks after injury , often in close association with implanted OECs or GDNF OECs -LRB- arrows -RRB-	27622
numerous NF-positive axons -LRB- green -RRB-	27622
numerous NF-positive axons	27622
the injury site 8 weeks after injury	27673
the injury site	27673
8 weeks	27689
injury	27703
close association with implanted OECs or GDNF OECs	27720
close association	27720
implanted OECs or GDNF OECs	27743
arrows	27772
the GDNF OEC group	27784
NF-positive axons	27804
bundles -LRB- arrowhead -RRB-	27842
bundles	27842
arrowhead	27851
Scale	27863
20 µm	27875
The bar graph	27882
grey levels of NF activity in the lesion in the different groups 8 weeks	27902
grey levels	27902
NF activity in the lesion in the different groups 8 weeks	27917
NF activity	27917
the lesion in the different groups 8 weeks	27932
the lesion	27932
the different groups	27946
8 weeks	27967
surgery	27981
NF immunoactivities	27990
animals receiving GDNF OECs than in those receiving normal OECs -LRB- P < 0.01 -RRB-	28041
animals	28041
GDNF OECs	28059
those receiving normal OECs -LRB- P < 0.01 -RRB-	28077
those	28077
normal OECs -LRB- P < 0.01 -RRB-	28093
normal OECs	28093
P < 0.01	28106
P	28106
< 0.01	28108
<	28108
0.01	28110
animals receiving OECs	28146
animals	28146
OECs	28164
those receiving DMEM	28177
those	28177
DMEM	28193
P <	28201
P	28201
<	28203
0.01	28205
DMEM group	28217
ΔΔP < 0.01 versus OEC group	28229
ΔΔP	28229
0.01	28235
OEC group	28247
ANOVA test	28258
least significant difference test , n = 5	28281
least significant difference test	28281
n = 5	28316
n	28316
5	28320
This figure	28323
colour	28352
supplementary material	28362
Brain Online	28388
Fig. 9 Photomicrographs showing HRP retrograde tracing of CSN -LRB- A , C , E , G -RRB- and RSN -LRB- B , D , F , H -RRB- 8 weeks after thoracic transection .	28403
Fig. 9 Photomicrographs	28403
Fig.	28403
9 Photomicrographs	28408
HRP	28435
CSN -LRB- A , C , E , G -RRB- and RSN -LRB- B , D , F , H -RRB- 8 weeks	28461
CSN -LRB- A , C , E , G -RRB-	28461
CSN	28461
A	28466
C	28469
E , G	28472
RSN -LRB- B , D , F , H -RRB-	28481
RSN	28481
B	28486
D , F , H	28489
8 weeks	28498
thoracic transection	28512
The dark purple-staining cells	28534
-LRB- A , B -RRB-	28583
A , B	28584
A	28584
B	28587
animal	28604
-LRB- C , D -RRB-	28612
group	28624
-LRB- E , F -RRB-	28631
E , F	28632
E	28632
F	28635
group	28642
-LRB- G , H -RRB- GDNF OEC group .	28649
G , H -RRB- GDNF	28650
group	28665
the DMEM group -LRB- control -RRB-	28675
the DMEM group	28675
control	28691
few HRP-labelled neurons	28701
the CSN or RSN	28743
animals	28762
OECs	28780
a few labelled cells	28791
Numerous HRP-labelled neurons	28827
the GDNF OEC group	28871
Scale	28891
200 µm	28903
This figure	28911
colour	28940
supplementary material	28950
Brain Online	28976
Fig. 10 Bar graph showing the numbers of HRP-labelled RSN and CSN among animal groups 8 weeks after surgery .	28991
Fig. 10 Bar graph	28991
the numbers of HRP-labelled RSN and CSN among animal groups 8 weeks	29017
the numbers of HRP-labelled RSN	29017
the numbers	29017
HRP-labelled RSN	29032
CSN among animal groups 8 weeks	29053
CSN	29053
animal groups 8 weeks	29063
animal groups	29063
8 weeks	29077
surgery	29091
animals	29103
GDNF OECs	29121
there	29132
significantly more RSN and CSN labelled than in those receiving normal OECs -LRB- P < 0.01 -RRB-	29143
significantly more RSN	29143
CSN labelled than in those receiving normal OECs -LRB- P < 0.01 -RRB-	29170
CSN	29170
those receiving normal OECs -LRB- P < 0.01 -RRB-	29191
those	29191
normal OECs -LRB- P < 0.01 -RRB-	29207
normal OECs	29207
P < 0.01	29220
P	29220
< 0.01	29222
<	29222
0.01	29224
More RSN and CSN	29231
More RSN	29231
CSN	29244
animals receiving OECs than in those receiving DMEM -LRB- P < 0.01 -RRB-	29265
animals	29265
OECs	29283
those receiving DMEM -LRB- P < 0.01 -RRB-	29296
those	29296
DMEM -LRB- P < 0.01 -RRB-	29312
DMEM	29312
P < 0.01	29318
P	29318
< 0.01	29320
<	29320
0.01	29322
P <	29331
P	29331
<	29333
0.01	29335
DMEM group	29347
ΔΔP < 0.01 versus OEC group	29359
ΔΔP	29359
0.01	29365
OEC group	29377
ANOVA test followed by the least significant difference test , n = 3 ± 5 .	29388
ANOVA test	29388
the least significant difference test , n	29411
the least significant difference test	29411
n	29450
3	29454
± 5	29455
Fig. 11 BDA-traced corticospinal axons in the lesion 8 weeks after implantation .	29460
Fig.	29460
11 BDA-traced corticospinal axons in the lesion 8 weeks after implantation	29465
11 BDA-traced corticospinal axons	29465
the lesion 8 weeks after implantation	29502
the lesion	29502
8 weeks	29513
implantation	29527
-LRB- A -RRB- Diagram of a sagittal spinal cord section containing the rostral part of the injury region .	29541
-LRB- A -RRB- Diagram of a sagittal spinal cord section	29541
-LRB- A -RRB-	29541
a sagittal spinal cord section	29556
the rostral part of the injury region	29598
the rostral part	29598
the injury region	29618
The locations of the images shown in C , F and I	29637
The locations	29637
the images shown in C , F and I	29654
the images	29654
C , F and I	29674
C	29674
F	29677
I	29683
box	29702
R = rostral ; V = ventral .	29708
R = rostral	29708
V = ventral	29721
V	29721
-LRB- B -RRB- Diagram of a sagittal spinal cord section containing the caudal part of the injury region .	29734
-LRB- B -RRB- Diagram of a sagittal spinal cord section	29734
-LRB- B -RRB-	29734
a sagittal spinal cord section	29749
the caudal part of the injury region	29791
the caudal part	29791
the injury region	29810
The locations of the images shown in E , H and K	29829
The locations	29829
the images shown in E , H and K	29846
the images	29846
E , H and K	29866
box	29894
C = caudal .	29900
C	29900
= caudal	29902
E	29919
the control group	29925
the transected CST	29944
little regeneration response	29970
the rostral end	30002
Few fibres	30019
the lesion	30057
the segment	30081
the lesion centre	30103
F , G , H	30123
the OEC group	30135
a few CST fibres	30150
termination bulbs and some fibres	30193
termination bulbs	30193
some fibres	30215
the lesion	30245
the segment	30268
the lesion centre	30290
I	30310
J , K	30313
the GDNF OEC group	30322
very robust fibre growth and termination bulb formation	30342
very robust fibre growth	30342
termination bulb formation	30371
many BDA-labelled axons	30417
the caudal end of the lesion	30454
the caudal end	30454
the lesion	30472
Scale	30484
50 µm	30496
C , F , I ; 100 µm in D , G , J ; 150 µm in E , H , K	30505
C	30505
F , I ; 100 µm in D , G , J ; 150 µm in E , H , K	30508
F , I	30508
F	30508
I	30511
100 µm in D , G , J	30514
100 µm	30514
D , G , J	30524
150 µm in E , H , K	30533
150 µm	30533
E , H , K	30543
This figure	30552
colour	30581
supplementary material	30591
Brain Online	30617
Fig. 12 Quantitative comparison of CST regrowth	30632
Fig. 12 Quantitative comparison	30632
Fig. 12	30632
CST regrowth	30667
grey matter of the transected spinal cord 8 weeks	30694
grey matter	30694
the transected spinal cord 8 weeks	30709
the transected spinal cord	30709
8 weeks	30736
implantation	30750
variations	30782
efficiency	30811
the cortical BDA injections	30825
the fibre number	30854
4.5 mm	30879
the centre of the lesion	30900
the centre	30900
the lesion	30914
100 %	30936
all data	30945
relative percentages	30973
the control group	30998
few CST fibres	31017
the distal spinal cord	31049
the normal OEC group	31076
a few CST fibres	31098
the lesion	31133
the segment	31156
the lesion centre	31178
the GDNF OEC group	31200
more CST regrowth	31229
more CST	31229
regrowth	31238
the segment near the injury side	31260
the segment	31260
the injury side	31277
P <	31295
P	31295
<	31297
0.05	31299
P < 0.01 versus DMEM group ; ΔP < 0.05 , ΔΔP < 0.01 versus OEC group	31307
P <	31307
P	31307
0.01 versus DMEM group	31311
0.01	31311
; ΔP < 0.05 , ΔΔP < 0.01 versus OEC group	31333
ΔP < 0.05	31335
ΔP <	31335
ΔP	31335
0.05	31340
ΔΔP < 0.01 versus OEC group	31346
ΔΔP	31346
0.01	31352
OEC group	31364
ANOVA test	31375
least significant difference test , n = 5	31398
least significant difference test	31398
n = 5	31433
n	31433
5	31437
Fig.	31441
13 Functional analysis of hindlimb movements following SCI among animal groups , using the BBB behavioural assessment -LRB- top -RRB- and the inclined plane -LRB- IP -RRB- test -LRB- bottom -RRB- * P < 0.05 , ** P < 0.01 versus control group ; ΔP < 0.05	31446
13 Functional analysis	31446
hindlimb movements following SCI among animal groups	31472
hindlimb movements	31472
SCI among animal groups	31501
SCI	31501
animal groups	31511
the BBB behavioural assessment -LRB- top -RRB- and the inclined plane -LRB- IP -RRB- test -LRB- bottom -RRB- * P <	31532
the BBB behavioural assessment -LRB- top -RRB- and the inclined plane -LRB- IP -RRB- test -LRB- bottom -RRB-	31532
the BBB behavioural assessment -LRB- top -RRB-	31532
the BBB behavioural assessment	31532
top	31564
the inclined plane -LRB- IP -RRB- test -LRB- bottom -RRB-	31573
the inclined plane -LRB- IP -RRB- test	31573
IP	31593
bottom	31603
P <	31612
P	31612
<	31614
P	31624
< 0.01 versus control group ; ΔP <	31626
<	31626
0.01 versus control group ; ΔP <	31628
0.01 versus control group	31628
0.01	31628
control group	31640
ΔP <	31655
ΔP	31655
<	31658
0.05	31660
ΔΔP < 0.01 versus OEC group	31666
ΔΔP	31666
0.01	31672
OEC group	31684
ANOVA test	31695
least significant difference test	31718
n = 8	31753
n	31753
8	31757
18	31759
Characterization of GDNF OECs	31764
Characterization	31764
GDNF OECs	31784
The GDNF OECs in primary cultures , which had a spindlelike morphology with two or three processes or a ¯ at appearance -LRB- Franceschini and Barnett , 1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al. , 2002 -RRB- , displayed S-100 immunoreactivity	31794
The GDNF	31794
OECs in primary cultures , which had a spindlelike morphology with two or three processes or a ¯ at appearance -LRB- Franceschini and Barnett , 1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al. , 2002 -RRB- ,	31803
OECs	31803
primary cultures	31811
a spindlelike morphology with two or three processes or a ¯	31839
a spindlelike morphology with two	31839
a spindlelike morphology	31839
two	31869
three processes or a ¯	31876
three processes	31876
a ¯	31895
appearance -LRB- Franceschini and Barnett , 1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al. , 2002 -RRB-	31901
appearance	31901
Franceschini and Barnett , 1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al. , 2002	31913
Franceschini and Barnett	31913
1996 ; Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31939
1996	31939
Li et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31945
Li	31945
et al. , 1998 ; Gudino-Cabrera et al. , 2000 ; Wewetzer et al.	31948
et al. , 1998	31948
et al.	31948
1998	31956
Gudino-Cabrera et al. , 2000	31962
Gudino-Cabrera	31962
et al. , 2000	31977
et al.	31977
2000	31985
Wewetzer et al.	31991
Wewetzer	31991
et al.	32000
2002	32008
S-100 immunoreactivity	32025
Fig. 2A and B	32049
Fig. 2A	32049
B	32061
Immuno	32065
uorescent staining	32072
the purity of GDNF OECs	32109
the purity	32109
GDNF OECs	32123
more than 92 %	32137
insertion of a new gene using a viral vector-mediated gene transfer	32178
insertion	32178
a new gene using a viral vector-mediated gene transfer	32191
a new gene	32191
a viral vector-mediated gene transfer	32208
normal cell functioning	32269
GDNF OEC cultures	32294
the expression of general cell markers : the low-affinity neurotrophin receptor p75NGFR , the Schwann cell marker S-100 , and GFAP	32345
the expression of general cell markers	32345
the expression	32345
general cell markers	32363
the low-affinity neurotrophin receptor p75NGFR , the Schwann cell marker S-100 , and GFAP	32385
the low-affinity neurotrophin receptor p75NGFR	32385
the Schwann cell marker S-100	32433
GFAP	32468
Fig. 2C and D	32486
GDNF OECs	32501
intensive immunostaining for p75 NGFR and weak immunostaining for GFAP	32540
intensive immunostaining for p75 NGFR	32540
intensive immunostaining	32540
p75 NGFR	32569
weak immunostaining for GFAP	32582
weak immunostaining	32582
GFAP	32606
A small amount of GFAP-positive cells that did not express p75NGFR	32612
A small amount	32612
GFAP-positive cells that did not express p75NGFR	32630
GFAP-positive cells	32630
p75NGFR	32671
astrocytes , as GFAP expression in astrocytes was much stronger than that in OECs	32693
astrocytes	32693
GFAP expression in astrocytes	32708
GFAP expression	32708
astrocytes	32727
that in OECs	32761
that	32761
OECs	32769
immunostain - ing for GDNF	32788
immunostain	32788
ing for GDNF	32801
ing	32801
GDNF	32809
GDNF OECs	32835
normal OECs	32853
Fig. 2E and F	32866
Fig. 2E	32866
F	32878
Ex vivo GDNF secretion and biological effect The amount of GDNF secreted by GDNF OECs	32882
Ex vivo GDNF secretion	32882
biological effect The amount of GDNF secreted by GDNF OECs	32909
biological effect	32909
The amount of GDNF	32927
The amount	32927
GDNF	32941
GDNF OECs	32958
ELISA	32986
detection sensitivity	32997
31.2 pg / ml of GDNF	33022
31.2 pg	33022
ml of GDNF	33031
ml	33031
GDNF	33037
GDNF production by uninfected OECs	33043
GDNF production	33043
uninfected OECs	33062
95 pg/ml per 106 cells	33099
95 pg/ml	33099
106 cells	33112
GDNF OECs	33131
an average of 25 ng GDNF/106 cells/day -LRB- Fig. 3 -RRB-	33150
an average	33150
25 ng GDNF/106 cells/day -LRB- Fig. 3 -RRB-	33164
25 ng GDNF/106 cells/day	33164
Fig. 3	33190
The biological activity of the secreted GDNF	33199
The biological activity	33199
the secreted GDNF	33226
the	33226
GDNF	33239
PC12-GFRa-Ret cells	33263
72 h of culture	33290
72 h	33290
culture	33298
CM from normal OECs	33309
CM	33309
normal OECs	33317
5.4 6 1.87 % of cells	33330
5.4 6 1.87 %	33330
5.4 6	33330
1.87 %	33336
cells	33345
CM from GDNF OECs	33379
CM	33379
GDNF OECs	33387
cell differentiation	33398
that of normal OECs -LRB- Fig. 4 -RRB-	33445
that	33445
normal OECs -LRB- Fig. 4 -RRB-	33453
normal OECs	33453
Fig. 4	33466
This bioassay	33475
GDNF secreted from GDNF OECs	33504
GDNF	33504
GDNF OECs	33523
PC12 - GFRa-Ret cell differentiation	33582
PC12	33582
GFRa-Ret cell differentiation	33588
Transgenetic gene expression of OECs in vivo Eight weeks	33619
Transgenetic gene expression	33619
OECs in vivo Eight weeks	33651
OECs	33651
vivo	33659
Eight weeks	33664
surgery	33682
RT-PCR	33691
the mRNA level of GDNF	33718
the mRNA level	33718
GDNF	33736
the injured spinal cord -LRB- Fig. 5 -RRB-	33744
the injured spinal cord	33744
Fig. 5	33769
injured spinal cord injected with GDNF OECs	33781
injured spinal cord	33781
GDNF OECs	33815
significantly higher levels of GDNF mRNA expression	33826
significantly higher levels	33826
GDNF mRNA expression	33857
that in the spinal cord of rats injected with normal OECs	33906
that	33906
the spinal cord of rats injected with normal OECs	33914
the spinal cord	33914
rats injected with normal OECs	33933
rats	33933
normal OECs	33952
This result	33965
ex vivo transduction of OECs with retrovectors	33995
ex vivo transduction	33995
OECs with retrovectors	34019
OECs	34019
retrovectors	34029
increased GDNF expression in vivo , up to at least 2 months after implantation	34067
increased GDNF expression	34067
vivo	34096
at least 2 months after implantation	34108
at least 2 months	34108
implantation	34132
the expression of the transgene and the location of OECs in the lesion	34165
the expression of the transgene	34165
the expression	34165
the transgene	34183
the location of OECs in the lesion	34201
the location	34201
OECs in the lesion	34217
OECs	34217
the lesion	34225
OECs	34237
the recombinant retrovirus containing green ¯ uorescent protein -LRB- GFP -RRB- , then implanted in the lesion of spinal cord	34261
the recombinant retrovirus	34261
green ¯ uorescent protein -LRB- GFP -RRB- , then implanted in the lesion of spinal cord	34299
green ¯ uorescent protein -LRB- GFP -RRB-	34299
green ¯ uorescent protein	34299
GFP	34325
the lesion of spinal cord	34349
the lesion	34349
spinal cord	34363
Fig. 6 , 2 months	34388
Fig. 6	34388
2 months	34396
implantation	34411
GFP-labelled OECs	34425
a dense mass of elongated , brightly	34462
a dense mass	34462
uorescent cells	34499
the lesion site	34530
Most GFPpositive implants	34547
p75NGFR	34597
These results	34606
the implanted OECs	34635
the injured spinal cord for at least 2 months	34683
the injured spinal cord	34683
at least 2 months	34711
implantation	34735
The OECs	34749
the lesion gap , which was surrounded by an intensively GFAPpositive border of reactive astrocytes	34775
the lesion gap	34775
an intensively GFAPpositive border of reactive astrocytes	34815
an intensively GFAPpositive border	34815
reactive astrocytes	34853
We	34874
OECs across the astrocytic barrier	34892
OECs	34892
the astrocytic barrier	34904
the spinal cord	34932
These results	34949
good agreement with previous report	34970
good agreement	34970
previous report	34990
Ruitenberg and colleagues -LRB- Ruitenberg et al. , 2002 -RRB-	35009
Ruitenberg and colleagues	35009
Ruitenberg	35036
et al. , 2002	35047
et al.	35047
2002	35055
Axonal regeneration Spinal cord transection lesion	35062
an obvious traverse scar at the T8 lesion epicentres and neuronal necrosis , reactive gliosis and cavitation	35134
an obvious traverse scar at the T8 lesion epicentres	35134
an obvious traverse scar	35134
the T8 lesion epicentres	35162
neuronal necrosis , reactive gliosis and cavitation	35191
neuronal necrosis	35191
reactive gliosis	35210
cavitation	35231
adjacent rostral and caudal regions -LRB- Fig. 7A and B -RRB-	35245
adjacent rostral and caudal regions	35245
Fig. 7A and B	35282
Fig. 7A	35282
B	35294
control animals	35301
2 months	35318
lesion	35333
only scattered NF-positive fibres	35340
the central scar	35388
many NF-immunoreactive fibres	35409
the host ± scar interface -LRB- Fig. 7C and D -RRB-	35455
the host ± scar interface	35455
Fig. 7C and D	35480
Fig. 7C	35480
D	35492
Fig. 7E and F	35508
Fig. 7E	35508
F	35520
NF-positive axons	35533
the lesion in normal OEC group	35574
the lesion	35574
normal OEC group	35588
increased amounts of NF-positive fibres	35619
increased amounts	35619
NF-positive fibres	35640
the lesion site in the GDNF OEC group	35673
the lesion site	35673
the GDNF OEC group	35692
some of them	35716
some	35716
them	35724
the invaded dorsal root -LRB- Fig. 7G and H -RRB-	35747
the invaded dorsal root	35747
Fig. 7G and H	35772
Fig. 7G	35772
H	35784
Highmagni fication microscopy	35788
numerous NF-positive axons growing through the lesion , often in close association with implanted OECs or GDNF OECs -LRB- Fig. 8 -RRB-	35825
numerous NF-positive axons	35825
the lesion	35868
close association with implanted OECs or GDNF OECs -LRB- Fig. 8 -RRB-	35889
close association	35889
implanted OECs or GDNF OECs	35912
Fig. 8	35941
the GDNF OEC group	35953
NF-positive axons	35973
bundles	36011
Statistical analysis	36020
significantly higher grey levels of NF immunoactivity	36050
significantly higher grey levels	36050
NF immunoactivity	36086
animals receiving GDNF OECs than in those receiving normal OECs	36107
animals	36107
GDNF OECs	36125
those receiving normal OECs	36143
those	36143
normal OECs	36159
Figure 9 shows RSN and CSN	36172
Figure 9 shows	36172
RSN and CSN	36187
injections of HRP	36215
injections	36215
HRP	36229
the low thoracic and upper lumbar region	36238
the low thoracic	36238
upper lumbar region	36259
HRP retrograde staining	36280
most labelled RSN	36316
most	36316
RSN	36330
the ventral ± lateral portion of the magnocellular nucleus of the red nucleus -LRB- Fig. 9B , D , F , H -RRB-	36350
the ventral ± lateral portion	36350
the magnocellular nucleus of the red nucleus -LRB- Fig. 9B , D , F , H -RRB-	36381
the magnocellular nucleus	36381
the red nucleus -LRB- Fig. 9B , D , F , H -RRB-	36410
the red nucleus	36410
Fig. 9B	36427
D , F , H	36436
Neurons in the cortex -LRB- Fig. 9A , C , E , G -RRB-	36446
Neurons	36446
the cortex -LRB- Fig. 9A , C , E , G -RRB-	36457
the cortex	36457
Fig. 9A	36469
C , E , G	36478
the RSN	36508
Fig. 10	36529
the number of HRP-labelled RSN and CSN	36538
the number	36538
HRP-labelled RSN and CSN	36552
HRP-labelled RSN	36552
CSN	36573
all groups of animals	36593
all groups	36593
animals	36607
average	36619
normal animals	36631
~ 386 and ~ 2737 neurons	36647
~ 386	36647
~ 2737 neurons	36656
both sides of the RSN and CSN	36687
both sides	36687
the RSN and CSN	36701
thoracic transection	36738
few HRP-labelled RSN or CSN	36760
few HRP-labelled RSN	36760
CSN	36784
the DMEM group	36805
treatment of normal OECs	36826
treatment	36826
normal OECs	36839
a few cells -LRB- RSN , 50 ; CSN , 355 -RRB- labelled with HRP	36852
a few cells -LRB- RSN , 50 ; CSN , 355 -RRB-	36852
a few cells	36852
RSN , 50 ; CSN , 355	36865
RSN	36865
50 ; CSN	36870
50	36870
CSN	36874
355	36879
HRP	36898
OEC transplantation	36917
a permissive environment that allowed a small percentage of axotomized neurons to regenerate into the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	36955
a permissive environment	36955
a small percentage of axotomized neurons to regenerate into the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	36993
a small percentage	36993
neurons	37026
the caudal spinal cord -LRB- P < 0.01 versus DMEM group -RRB-	37053
the caudal spinal cord	37053
P	37077
0.01	37081
DMEM group	37093
The highest regeneration ratio	37106
the GDNF OEC group -LRB- approximately 97 in RSN and 776 in CSN were labelled with HRP -RRB-	37144
the GDNF OEC group	37144
approximately 97 in RSN and 776 in CSN	37164
approximately 97 in RSN	37164
approximately 97	37164
RSN	37184
776 in CSN	37192
776	37192
CSN	37199
HRP	37222
These numbers	37228
signifi - cantly higher	37247
signifi	37247
those in the normal OEC group -LRB- P < 0.01 -RRB-	37275
those	37275
the normal OEC group -LRB- P < 0.01 -RRB-	37284
the normal OEC group	37284
P < 0.01	37306
P	37306
< 0.01	37308
<	37308
0.01	37310
the axonal regeneration	37336
antegrade tracing experiments	37361
antegrade	37361
experiments	37379
Figure 11	37407
the images for BDA-traced corticospinal axons 8 weeks	37423
the images	37423
BDA-traced corticospinal axons 8 weeks	37438
BDA-traced corticospinal axons	37438
8 weeks	37469
spinal cord injury	37483
the control group	37506
the transected CST	37525
little regeneration response	37551
the segment rostral	37583
the lesion centre	37606
the normal OEC group	37637
a few CST fibres	37658
termination bulbs	37701
some fibres	37723
the lesion	37753
the segment	37776
the lesion centre	37798
Quantitative analysis	37817
more BDA-traced CST fibres	37853
the segment near the injury side in the GDNF OEC group	37894
the segment	37894
the injury side in the GDNF OEC group	37911
the injury side	37911
the GDNF OEC group	37930
a distal segment 4.5 mm away from the lesion centre	37968
a distal segment	37968
4.5 mm	37985
the lesion centre	38002
no significant differences	38021
the OEC and GDNF OEC groups -LRB- Fig. 12 -RRB-	38067
the OEC	38067
GDNF OEC groups -LRB- Fig. 12 -RRB-	38079
GDNF OEC groups	38079
Fig. 12	38096
Behavioural assessment Figure 13	38106
Behavioural assessment Figure	38106
13	38136
the behavioural results	38145
the 8-week assessment period for each group of animals	38176
the 8-week assessment period	38176
each group of animals	38209
each group	38209
animals	38223
All injured rats	38232
complete hind limb paralysis	38260
injury	38307
The BBB scores	38315
the range of 0 ±	38338
the range	38338
0 ±	38351
2 in the control animals	38353
2	38353
the control animals	38358
transplantation of the OECs	38389
transplantation	38389
the OECs	38408
hind limb functional recovery	38418
hind limb	38418
functional recovery	38428
8 weeks	38469
transplantation	38483
all 15 animals	38500
BBB scores greater than that achieved by any of the eight controls -LRB- P < 0.01 -RRB-	38525
that achieved by any of the eight	38549
that	38549
any of the eight	38566
any	38566
the eight	38573
P < 0.01	38593
P	38593
< 0.01	38595
<	38595
0.01	38597
Five of the 15 experimental animals from the OEC group	38604
Five	38604
the 15 experimental animals from the OEC group	38612
the 15 experimental animals	38612
the OEC group	38645
their body weight	38673
their hind limbs	38694
the other 10 animals	38712
ankle , knee and hip movements in one or both legs	38737
ankle , knee and hip movements	38737
one or both legs	38770
one	38770
both legs	38777
weight	38814
The GDNF OEC group	38822
more functional recovery	38850
the normal OEC group	38880
8 weeks	38901
transplantation	38915
P < 0.01	38932
P	38932
< 0.01	38934
<	38934
0.01	38936
10 of the 18 rats treated with GDNF OECs	38943
10	38943
the 18 rats treated with GDNF OECs	38949
the 18 rats	38949
GDNF OECs	38974
a coordinated manner	38998
Differences in score on the inclined plane test among the three groups	39020
Differences	39020
score on the inclined plane test among the three groups	39035
score	39035
the inclined plane test among the three groups	39044
the inclined plane test	39044
the three groups	39074
2 weeks after operation	39119
2 weeks	39119
operation	39133
rats in the OEC group	39144
rats	39144
the OEC group	39152
more functional recovery	39180
those in the control group -LRB- P < 0.05 -RRB-	39210
those	39210
the control group -LRB- P < 0.05 -RRB-	39219
the control group	39219
P < 0.05	39238
P	39238
< 0.05	39240
<	39240
0.05	39242
5 weeks	39255
implantation animals in the GDNF OEC group	39269
implantation animals	39269
the GDNF OEC group	39293
a higher score than those in the OEC group -LRB- P < 0.05 -RRB-	39316
a higher score	39316
those in the OEC group -LRB- P < 0.05 -RRB-	39336
those	39336
the OEC group -LRB- P < 0.05 -RRB-	39345
the OEC group	39345
P < 0.05	39360
P	39360
< 0.05	39362
<	39362
0.05	39364
Discussion Combining transplantation and gene therapy	39372
Discussion Combining transplantation	39372
gene therapy	39413
one of the most powerful strategies	39437
one	39437
the most powerful strategies	39444
CNS repair	39484
implantation of OECs in the injured spinal cord	39499
implantation	39499
OECs in the injured spinal cord	39515
OECs	39515
the injured spinal cord	39523
long-distance regeneration and func - tional recovery following SCI -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	39576
long-distance regeneration and func	39576
tional recovery following SCI -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	39613
tional recovery	39613
SCI -LRB- Li et al. , 1997 ; Ramon-Cueto et al. , 2000 -RRB-	39639
SCI	39639
Li	39644
et al. , 1997 ; Ramon-Cueto et al. , 2000	39647
et al.	39647
1997 ; Ramon-Cueto et al.	39655
1997	39655
Ramon-Cueto et al.	39661
Ramon-Cueto	39661
et al.	39673
2000	39681
there	39688
much interest in upgrading OECs to enhance the regenerative properties of these cells	39697
much interest	39697
OECs	39724
the regenerative properties of these cells	39740
the regenerative properties	39740
these cells	39771
researchers	39794
OECs	39830
uorescent markers	39847
experiments -LRB- Ruitenberg et al. , 2002 -RRB-	39877
experiments	39877
Ruitenberg	39890
et al. , 2002	39901
et al.	39901
2002	39909
transgenic animals expressing a xenogeneic protein as a source for modified OECs -LRB- Imaizumi et al. , 2000 -RRB-	39925
transgenic animals	39925
a xenogeneic protein	39955
a source for modified OECs -LRB- Imaizumi et al. , 2000 -RRB-	39979
a source	39979
modified OECs -LRB- Imaizumi et al. , 2000 -RRB-	39992
modified OECs	39992
Imaizumi	40007
et al. , 2000	40016
et al.	40016
2000	40024
the present study	40034
OECs	40053
exogenous neurotrophic factor	40099
the transected spinal cord	40156
Ex vivo gene therapy	40184
Ex vivo gene	40184
therapy	40197
a valuable approach to the achievement of long-term and site-specific delivery of therapeutic agents in the CNS	40208
a valuable approach	40208
the achievement of long-term and site-specific delivery of therapeutic agents in the CNS	40231
the achievement	40231
long-term and site-specific delivery of therapeutic agents in the CNS	40250
long-term and site-specific delivery	40250
therapeutic agents in the CNS	40290
therapeutic agents	40290
the CNS	40312
Both retroviral and adenovirus vectors	40321
gene transfer	40386
Retrovectors	40401
high efficiency	40429
no viral genes	40457
they	40475
long-term expression	40492
host cellular immune responses -LRB- Robbins et al. , 1998 -RRB-	40523
host cellular immune responses	40523
host	40523
Robbins et al. , 1998	40555
Robbins	40555
et al.	40563
1998	40571
the present study	40581
high levels of transgenic GDNF mRNA	40600
high levels	40600
transgenic GDNF mRNA	40615
even 2 months	40654
implantation	40674
the GFP OECs	40696
the	40724
genetically modified OECs	40739
the foreign gene in the spinal cord lesion	40806
the foreign gene	40806
the spinal cord lesion	40826
The sustained high-level expression of GDNF in OEC implants	40850
The sustained high-level expression	40850
GDNF in OEC implants	40889
GDNF	40889
OEC implants	40897
the possibility of manipulating the growth-promoting properties of OECs and the microenvironment at the lesion site not only during the acute but also during the chronic phase following injury	40917
the possibility	40917
the growth-promoting properties of OECs and the microenvironment	40949
the growth-promoting properties	40949
OECs and the microenvironment	40984
OECs	40984
the microenvironment	40993
the lesion site	41017
the acute	41049
the chronic phase following injury	41075
the chronic phase	41075
injury	41103
Retrovectors	41111
the viral LTR sequence , which may interfere with the expression of various gene cassettes	41139
the viral LTR sequence	41139
the expression of various gene cassettes	41188
the expression	41188
various gene cassettes	41206
No changes in morphology and expression of general cell marker proteins	41230
No changes	41230
morphology and expression of general cell marker proteins	41244
morphology and expression	41244
general cell marker proteins	41273
transduction of OECs	41322
transduction	41322
OECs	41338
retroviral vectors in this study	41346
retroviral vectors	41346
this study	41368
ex vivo gene transfer , implants of transduced OECs into the site of a spinal cord lesion	41390
ex vivo gene transfer	41390
implants of transduced OECs into the site of a spinal cord lesion	41413
implants	41413
OECs	41436
the site of a spinal cord lesion	41446
the site	41446
a spinal cord lesion	41458
typical bipolar morphology , suggesting that gene transfer with retroviral pN2A-GDNF vectors did not interfere with normal cell functioning	41515
typical bipolar morphology	41515
gene transfer with retroviral pN2A-GDNF vectors	41559
gene transfer	41559
retroviral pN2A-GDNF vectors	41578
normal cell functioning	41630
GDNF	41655
a potent trophic factor for midbrain dopaminergic neurons -LRB- Lin et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995 -RRB-	41689
a potent trophic factor	41689
midbrain dopaminergic neurons -LRB- Lin et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995 -RRB-	41717
midbrain dopaminergic neurons	41717
Lin et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995	41748
Lin	41748
et al. , 1993 ; Beck et al. , 1995 ; Tomac et al. , 1995	41752
et al. , 1993	41752
et al.	41752
1993	41760
Beck et al. , 1995	41766
Beck	41766
et al. , 1995	41771
et al.	41771
1995	41779
Tomac et al. , 1995	41785
Tomac	41785
et al. , 1995	41791
et al.	41791
1995	41799
It	41806
GDNF	41837
the survival of motoneurons both in vitro	41865
the survival	41865
motoneurons	41881
vivo -LRB- Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995 ; Yan et al. , 1995 ; Houenou et al. , 1996 -RRB-	41914
vivo	41914
Henderson et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995 ; Yan et al. , 1995 ; Houenou et al. , 1996	41920
Henderson	41920
et al. , 1994 ; Li et al. , 1995 ; Oppenheim et al. , 1995 ; Yan et al. , 1995 ; Houenou et al. , 1996	41930
et al. , 1994	41930
et al.	41930
1994	41938
Li et al. , 1995	41944
Li	41944
et al. , 1995	41947
et al.	41947
1995	41955
Oppenheim et al. , 1995	41961
Oppenheim	41961
et al. , 1995	41971
et al.	41971
1995	41979
Yan et al. , 1995	41985
Yan	41985
et al. , 1995	41989
et al.	41989
1995	41997
Houenou et al. , 1996	42003
Houenou	42003
et al. , 1996	42011
et al.	42011
1996	42019
the spinal cord	42044
GDNF	42061
a trophic effect	42073
corticospinal neurons	42093
their long-term survival	42128
axotomy -LRB- Giehl et al. , 1997 -RRB-	42159
axotomy	42159
Giehl	42168
et al. , 1997	42174
et al.	42174
1997	42182
the present study	42192
we	42211
treatment with OECs with a modified GDNF gene	42231
treatment	42231
OECs with a modified GDNF gene	42246
OECs	42246
a modified GDNF gene	42256
an increase in the regeneration of corticospinal or rubrospinal axons in adult rats	42293
an increase	42293
the regeneration of corticospinal or rubrospinal axons in adult rats	42308
the regeneration	42308
corticospinal or rubrospinal axons in adult rats	42328
corticospinal or rubrospinal axons	42328
adult rats	42366
spinal cord transection compared with treatment with normal OECs	42383
spinal cord transection	42383
treatment with normal OECs	42421
treatment	42421
normal OECs	42436
The HRP retrograde labelling studies	42449
injured axons	42512
the transection site	42557
Numerous HRP-labelled neurons	42579
8 weeks	42623
SCI in the GDNF OEC group	42637
SCI	42637
the GDNF OEC group	42644
the normal OEC group	42676
less than half of the HRP-labelled neurons	42698
less than half	42698
the HRP-labelled neurons	42716
BDA antegrade tracing experiments	42756
BDA antegrade	42756
experiments	42778
more CST fibres	42805
the lesion	42839
the segment	42862
the lesion centre in the GDNF OEC group	42884
the lesion centre	42884
the GDNF OEC group	42905
the normal OEC group	42932
NF immunochemical labelling	42954
large number of fibres	42994
large number	42994
fibres	43010
the lesioned spinal cord following GDNF OEC injections	43020
the lesioned spinal cord	43020
GDNF OEC injections	43055
These results	43076
GDNF ex vivo gene delivery	43103
GDNF	43103
ex vivo gene delivery	43108
the growth-promoting properties of OECs	43144
the growth-promoting properties	43144
OECs	43179
SCI	43190
There	43195
several possible explanations for this phenomenon	43205
several possible explanations	43205
this phenomenon	43239
GDNF	43263
a chemotropic effect	43276
the growth of axons	43308
the growth	43308
axons	43322
regions with the highest concentration of growth factor	43331
regions	43331
the highest concentration of growth factor	43344
the highest concentration	43344
growth factor	43373
GDNF	43398
the survival ratio of RSN and CSN	43416
the survival ratio	43416
RSN and CSN	43438
axotomy , which results in an increased number of regenerated corticospinal or rubrospinal fibres	43456
axotomy	43456
an increased number of regenerated corticospinal or rubrospinal fibres	43482
an increased number	43482
regenerated corticospinal or rubrospinal fibres	43505
recent studies	43564
OECs	43609
GDNF receptor GFRa1 -LRB- Woodhall et al. , 2001 -RRB-	43622
GDNF receptor GFRa1	43622
Woodhall	43643
et al. , 2001	43652
et al.	43652
2001	43660
high levels of GDNF secreted from GDNF OECs	43678
high levels	43678
GDNF secreted from GDNF OECs	43693
GDNF	43693
GDNF OECs	43712
trophic effects on themselves	43731
trophic effects	43731
themselves	43750
The locomotor functions of animals	43762
The locomotor functions	43762
animals	43789
the inclined plane method of Rivlin and BBB scale	43818
plane method of Rivlin and BBB	43831
plane method	43831
Rivlin and BBB	43847
The BBB scoring system	43869
other locomotor scoring systems in several respects	43905
other locomotor scoring systems	43905
several respects	43940
the score	43965
a summation of component behaviours	43982
a summation	43982
component behaviours	43997
Each BBB score	44019
fulfilment of a unique set of criteria	44043
fulfilment	44043
a unique set of criteria	44057
a unique set	44057
criteria	44073
the scores	44093
many behavioural traits	44114
a detailed characterization of rat locomotor function	44152
a detailed characterization	44152
rat locomotor function	44183
the scores	44216
observations of rat recovery	44240
observations	44240
rat recovery	44256
SCI	44274
The ordering of the scores	44279
The ordering	44279
the scores	44295
progressive recovery	44314
each recovery stage	44344
better locomotion	44375
the preceding stage -LRB- Basso et al. , 1996 -RRB-	44398
the preceding stage	44398
Basso	44419
et al. , 1996	44425
et al.	44425
1996	44433
the BBB scale and the inclined plane method	44446
the BBB scale	44446
the inclined plane method	44464
we	44491
a progressive recovery	44507
time	44535
three groups	44546
The functional recovery in the GDNF OEC group	44560
The functional recovery	44560
the GDNF OEC group	44587
statistically signi ®	44613
cant improvements	44633
the normal OEC group	44665
This result	44687
accordance with the morphological experiments	44705
accordance	44705
the morphological experiments	44721
Significant improvements of locomotor function	44752
Significant improvements	44752
locomotor function	44780
the GDNF OEC and normal OEC groups	44821
the GDNF OEC	44821
normal OEC groups	44838
the control group	44870
The enhanced recovery of function in the GDNF OEC group	44889
The enhanced recovery	44889
function in the GDNF OEC group	44914
function	44914
the GDNF OEC group	44926
the enhanced outgrowth of a still very limited number of nerve fibres	44977
the enhanced outgrowth	44977
a still very limited number of nerve fibres	45003
a still very limited number	45003
nerve fibres	45034
our retrograde	45061
results	45098
spinal cord transection	45113
rats from the control group	45138
rats	45138
the control group	45148
severe tissue loss	45177
the transection centre	45204
A positive correlation of the increased tissue sparing with higher locomotor scores after SCI	45228
A positive correlation	45228
the increased tissue sparing with higher locomotor scores after SCI	45254
the increased tissue	45254
higher locomotor scores	45288
SCI	45318
Basso et al. , 1996	45352
Basso	45352
et al.	45358
1996	45366
It	45373
the transplanted OECs	45396
a beneficial effect on tissue sparing	45423
a beneficial effect	45423
tissue sparing	45446
other investigators in recent publications -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	45474
other investigators	45474
recent publications -LRB- Takami et al. , 2002 ; Plant et al. , 2003 -RRB-	45497
recent publications	45497
Takami	45518
et al. , 2002 ; Plant et al. , 2003	45525
et al.	45525
2002 ; Plant et al.	45533
2002	45533
Plant et al.	45539
Plant	45539
et al.	45545
2003	45553
GDNF secreted by the OEC	45570
GDNF	45570
the OEC	45587
the tissue loss	45615
the GDNF administration	45635
tissue sparing	45684
a contusion model -LRB- Cheng et al. , 2002 -RRB-	45702
a contusion model	45702
Cheng	45721
et al. , 2002	45727
et al.	45727
2002	45735
GDNF secreted by the OEC	45755
GDNF	45755
the OEC	45772
the repair or survival of spinal motor neurons , which may have contributed to the functional recovery -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	45800
the repair or survival	45800
spinal motor neurons , which may have contributed to the functional recovery -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	45826
spinal motor neurons	45826
the functional recovery -LRB- Watabe et al. , 2000 ; Cheng et al. , 2002 -RRB-	45878
the functional recovery	45878
Watabe	45903
et al. , 2000 ; Cheng et al. , 2002	45910
et al.	45910
2000 ; Cheng et al.	45918
2000	45918
Cheng et al.	45924
Cheng	45924
et al.	45930
2002	45938
summary	45948
the present study	45957
the growthpromoting properties of OECs	45986
the growthpromoting properties	45986
OECs	46020
these cells	46058
an increased level of GDNF	46107
an increased level	46107
GDNF	46129
Genetic engineering of OECs	46135
Genetic engineering	46135
OECs	46158
new possibilities for future clinical applications in SCI	46172
new possibilities	46172
future clinical applications in SCI	46194
future clinical applications	46194
SCI	46226
Note added in proof	46232
Note	46232
proof	46246
this manuscript	46255
revision Ruitenberg	46281
et al. -LRB- 2003 -RRB- published their paper which addresses the point of the effect of genetically modified OECs on tissue sparing	46301
et al.	46301
2003	46309
their paper which addresses the point of the effect of genetically modified OECs on tissue sparing	46325
their paper	46325
the point of the effect of genetically modified OECs on tissue sparing	46353
the point	46353
the effect of genetically modified OECs on tissue sparing	46366
the effect	46366
genetically modified OECs on tissue sparing	46380
genetically modified OECs	46380
tissue sparing	46409
Their results	46425
the notion	46459
the behavioural effect observed in the present study	46475
the behavioural effect	46475
the present study	46510
this way	46557
Acknowledgements	46568
We	46585
Professor Xuan Bao for her helpful suggestions and valuable comments	46594
Professor Xuan Bao	46594
her helpful suggestions and valuable comments	46617
her helpful suggestions	46617
valuable comments	46645
We	46664
Dr Karin Beloussow and Dr Xu Zhang	46673
the manuscript	46731
The pN2A vector	46747
Professor Baoyu Guo	46786
This work	46807
Shanghai Biotech and Drug R & D Program -LRB- 004319203 -RRB- , National Natural Science Foundation 30325022 and the National Basic Research Program -LRB- G199905400 -RRB- of China	46834
Shanghai Biotech and Drug R & D Program -LRB- 004319203 -RRB- , National Natural Science Foundation 30325022 and the National Basic Research Program -LRB- G199905400 -RRB-	46834
Shanghai Biotech and Drug R & D Program -LRB- 004319203 -RRB- , National Natural Science Foundation 30325022 and the National Basic Research Program	46834
Shanghai Biotech and Drug R & D Program	46834
Shanghai Biotech	46834
Drug R & D Program	46855
004319203	46875
National Natural Science Foundation 30325022	46887
the National Basic Research Program	46936
G199905400	46973
China	46988
References Barnett SC , Alexander CL , Iwashita Y , Gilson JM , Crowther J , Clark L , et al. .	46996
References	46996
Barnett SC , Alexander CL , Iwashita Y , Gilson JM , Crowther J , Clark L , et al.	47007
Barnett SC	47007
Alexander CL	47019
Iwashita Y	47033
Gilson JM	47045
Crowther J	47056
Clark L	47068
et al.	47077
Identi ® cation of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons .	47084
Identi ® cation	47084
a human olfactory ensheathing cell that can effect transplant-mediated remyelination	47101
a human olfactory ensheathing cell	47101
transplant-mediated remyelination	47152
CNS axons	47202
Brain 2000 ; 123 : 1581 ± 8 .	47213
Brain 2000	47213
123 : 1581 ± 8	47225
123 : 1581	47225
8	47235
Basso DM , Beattie MS , Bresnahan JC .	47238
Basso DM	47238
Beattie MS , Bresnahan JC	47248
Beattie MS	47248
Bresnahan JC	47260
histological and locomotor outcomes	47281
spinal cord contusion	47323
the NYU weight-drop device versus transection	47351
the NYU weight-drop device	47351
transection	47385
Exp Neurol 1996 ; 139 : 244 ± 56 .	47398
Exp Neurol 1996	47398
139 : 244 ± 56	47415
139 : 244	47415
56	47424
Beck KD , Valverde J , Alexi T , Poulsen K , Moffat B , Vandlen RA , et al. .	47428
Beck KD	47428
Valverde J , Alexi T , Poulsen K , Moffat B , Vandlen RA , et al.	47437
Valverde J	47437
Alexi T	47449
Poulsen K	47458
Moffat B	47469
Vandlen RA	47479
et al.	47491
Mesencephalic dopaminergic neurons	47498
GDNF	47546
axotomyinduced degeneration	47556
the adult brain	47587
Nature 1995 ; 373 : 339 ± 41 .	47604
Nature 1995	47604
373 : 339 ± 41	47617
373 : 339	47617
41	47626
Blesch A , Tuszynski MH .	47630
Blesch A	47630
Tuszynski MH	47640
GDNF gene delivery to injured adult CNS motor neurons	47654
GDNF gene delivery	47654
injured adult CNS motor neurons	47676
injured adult CNS	47676
motor neurons	47694
axonal growth , expression of the trophic neuropeptide CGRP , and cellular protection	47717
axonal growth	47717
expression of the trophic neuropeptide CGRP	47732
expression	47732
the trophic neuropeptide CGRP	47746
cellular protection	47781
J Comp Neurol 2001 ; 436 : 399 ± 410 .	47802
J Comp Neurol 2001 ; 436	47802
J Comp Neurol	47802
2001 ; 436	47816
399 ± 410	47827
399 ±	47827
410	47831
Blits B , Dijkhuizen PA , Carlstedt TP , Poldervaart H , Schiemanck S , Boer GJ , et al. .	47836
Blits B	47836
Dijkhuizen PA , Carlstedt TP , Poldervaart H , Schiemanck S , Boer GJ , et al.	47845
Dijkhuizen PA	47845
Carlstedt TP	47860
Poldervaart H	47874
Schiemanck S	47889
Boer GJ	47903
et al.	47912
Adenoviral vector-mediated expression of a foreign gene in peripheral nerve tissue bridges	47919
Adenoviral vector-mediated expression	47919
a foreign gene in peripheral nerve tissue bridges	47960
a foreign gene	47960
peripheral nerve tissue bridges	47978
the injured peripheral and central nervous system	48023
the injured peripheral	48023
central nervous system	48050
Exp Neurol 1999 ; 160 : 256 ± 67 .	48074
Exp Neurol 1999	48074
160 : 256 ± 67	48091
160 : 256	48091
67	48100
Blits B , Dijkhuizen PA , Boer GJ , Verhaagen J. Intercostal nerve implants transduced with an adenoviral vector encoding neurotrophin-3	48104
Blits B , Dijkhuizen PA , Boer GJ , Verhaagen J. Intercostal nerve implants	48104
Blits B	48104
Dijkhuizen PA	48113
Boer GJ	48128
Verhaagen J. Intercostal nerve implants	48137
Verhaagen J.	48137
Intercostal nerve implants	48150
an adenoviral vector encoding neurotrophin-3	48193
an adenoviral vector	48193
neurotrophin-3	48223
regrowth of injured rat corticospinal tract ® bers	48246
regrowth	48246
injured rat corticospinal tract ® bers	48258
hindlimb function	48308
Exp Neurol 2000 ; 164 : 25 ± 37 .	48327
Exp Neurol 2000 ; 164	48327
Exp Neurol	48327
2000 ; 164	48338
25 ± 37	48349
25 ±	48349
37	48352
Blits B , Boer GJ , Verhaagen J. Pharmacological , cell , and gene therapy strategies to promote spinal cord regeneration .	48356
Blits B	48356
Boer GJ	48365
Verhaagen J. Pharmacological , cell , and gene therapy strategies to promote spinal cord regeneration	48374
Verhaagen J.	48374
Pharmacological , cell , and gene therapy strategies	48387
spinal cord regeneration	48449
Cell Transplant 2002 ; 11 : 593 ± 613 .	48475
Cell Transplant 2002 ; 11	48475
Cell Transplant	48475
2002 ; 11	48491
593 ± 613	48501
593 ±	48501
613	48505
Boruch AV , Conners JJ , Pipitone M , Deadwyler G , Storer PD , Devries GH , et al. .	48510
Boruch AV	48510
Conners JJ , Pipitone M , Deadwyler G , Storer PD , Devries GH , et al.	48521
Conners JJ	48521
Pipitone M	48533
Deadwyler G	48545
Storer PD	48558
Devries GH	48569
et al.	48581
Neurotrophic and migratory properties of an olfactory ensheathing cell line .	48588
Neurotrophic and migratory properties	48588
an olfactory ensheathing cell line	48629
Glia 2001 ; 33 : 225 ± 9 .	48665
Glia 2001	48665
33 : 225 ± 9	48676
33 : 225	48676
9	48684
Chan JR , Cosgaya JM , Wu YJ , Shooter EM .	48687
Chan JR	48687
Cosgaya JM	48696
Wu YJ	48708
Shooter EM	48715
Neurotrophins	48727
key mediators of the myelination program in the peripheral nervous system	48745
key mediators	48745
the myelination program in the peripheral nervous system	48762
the myelination program	48762
the peripheral nervous system	48789
Proc Natl Acad Sci USA 2001 ; 98 : 14661 ± 8 .	48820
Proc Natl Acad Sci USA 2001	48820
98 : 14661 ± 8	48849
98 : 14661	48849
8	48859
Chen ZY , Sun JX , Li JH , He C , Lu CL , Wu XF .	48862
Chen ZY	48862
Sun JX , Li JH , He C , Lu CL , Wu XF	48871
Sun JX	48871
Li JH	48879
He C	48886
Lu CL	48892
Wu XF	48899
Preparation of recombinant human GDNF by baculovirus expression system and analysis of its biological activities .	48906
Preparation	48906
recombinant human GDNF	48921
baculovirus expression system and analysis	48947
baculovirus expression system	48947
analysis	48981
its biological activities	48993
Biochem Biophys Res Commun 2000 ; 273 : 902 ± 6 .	49020
Biochem Biophys Res Commun 2000	49020
273 : 902 ± 6	49053
273 : 902	49053
6	49062
Chen Z , Chai Y , Cao L , Huang A , Cui R , Lu C , et al. .	49065
Chen Z	49065
Chai Y , Cao L , Huang A , Cui R , Lu C , et al.	49073
Chai Y	49073
Cao L	49081
Huang A	49088
Cui R	49097
Lu C	49104
et al.	49110
Glial cell line-derived neurotrophic factor	49117
Glial cell	49117
line-derived neurotrophic factor	49128
survival	49170
differentiation	49191
the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathway	49215
the phosphatidylinositol 3-kinase	49215
mitogen-activated protein kinase pathway	49253
PC12 cells	49310
Neuroscience 2001 ; 104 : 593 ± 8 .	49322
Neuroscience 2001	49322
104 : 593 ± 8	49341
104 : 593	49341
8	49350
Cheng H , Wu JP , Tzeng SF .	49353
Cheng H	49353
Wu JP , Tzeng SF	49362
Wu JP	49362
Tzeng SF	49369
Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury .	49379
Neuroprotection	49379
glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury	49398
glial cell	49398
line-derived neurotrophic factor in damaged spinal cords following contusive injury	49409
line-derived neurotrophic factor	49409
damaged spinal cords following contusive injury	49445
damaged spinal cords	49445
contusive injury	49476
J Neurosci Res 2002 ; 69 : 397 ± 405 .	49494
J Neurosci Res 2002 ; 69	49494
J Neurosci Res	49494
2002 ; 69	49509
397 ± 405	49519
397 ±	49519
405	49523
Cosgaya JM , Chan JR , Shooter EM .	49528
Cosgaya JM	49528
Chan JR , Shooter EM	49540
Chan JR	49540
Shooter EM	49549
The neurotrophin receptor p75NTR as a positive modulator of myelination .	49561
The neurotrophin receptor p75NTR	49561
a positive modulator	49597
myelination	49621
Science 2002 ; 298 : 1245 ± 8 .	49634
Science 2002	49634
298 : 1245 ± 8	49648
298 : 1245	49648
8	49658
Doucette JR. .	49661
The glial cells in the nerve ® bre layer of rat olfactory bulb .	49674
The glial cells	49674
the nerve ® bre layer	49693
rat olfactory bulb	49717
Anat Re 1984 ; 210 : 385 ± 91 .	49737
Anat Re 1984	49737
210 : 385 ± 91	49751
210 : 385	49751
91	49760
Franceschini IA , Barnett SC .	49764
Franceschini IA	49764
Barnett SC	49781
Low-af ® nity NGF-receptor and E-N-CAM expression de ® ne two types of olfactory nerve ensheathing cells that share a common lineage .	49793
Low-af ® nity NGF-receptor and E-N-CAM expression	49793
® ne two types of olfactory nerve ensheathing cells that share a common lineage	49843
® ne two types	49843
olfactory nerve ensheathing cells	49860
a common lineage	49905
Dev Biol 1996 ; 173 : 327 ± 43 .	49923
Dev Biol 1996	49923
173 : 327 ± 43	49938
173 : 327	49938
43	49947
Giehl KM , Schacht CM , Yan Q , Mestres P. GDNF	49951
Giehl KM	49951
Schacht CM	49961
Yan Q	49973
Mestres P. GDNF	49980
a trophic factor for adult rat corticospinal neurons	49999
a trophic factor	49999
adult rat corticospinal neurons	50020
adult rat	50020
corticospinal neurons	50030
their long-term survival	50065
axotomy in vivo	50096
axotomy	50096
vivo	50107
Eur J Neurosci 1997 ; 9 : 2479 ± 88 .	50113
Eur J Neurosci 1997	50113
9 : 2479 ± 88	50134
9 : 2479	50134
88	50142
Giehl KM , Rohrig S , Bonatz H , Gutjahr M , Leiner B , Bartke I , et al. .	50146
Giehl KM	50146
Rohrig S , Bonatz H , Gutjahr M , Leiner B , Bartke I , et al.	50156
Rohrig S	50156
Bonatz H	50166
Gutjahr M	50176
Leiner B	50187
Bartke I	50197
Bartke	50197
I	50204
et al.	50207
Endogenous brain-derived neurotrophic factor and neurotrophin-3	50214
Endogenous brain-derived neurotrophic factor	50214
neurotrophin-3	50263
survival of axotomized corticospinal neurons in vivo	50304
survival	50304
axotomized corticospinal neurons in vivo	50316
axotomized corticospinal neurons	50316
vivo	50352
J Neurosci 2001 ; 21 : 3492 ± 502 .	50358
J Neurosci 2001 ; 21	50358
J Neurosci	50358
2001 ; 21	50369
3492 ± 502	50379
3492 ±	50379
502	50384
Grill RJ , Blesch A , Tuszynski MH .	50389
Grill RJ	50389
Blesch A , Tuszynski MH	50399
Blesch A	50399
Tuszynski MH	50409
Robust growth of chronically injured spinal cord axons	50423
Robust growth	50423
chronically injured spinal cord axons	50440
grafts of genetically modi ® ed NGF-secreting cells	50489
grafts	50489
genetically modi ® ed NGF-secreting cells	50499
genetically modi ®	50499
NGF-secreting cells	50519
Exp Neurol 1997a ; 148 : 444 ± 52 .	50540
Exp Neurol 1997a	50540
148 : 444 ± 52	50558
148 : 444	50558
52	50567
Grill R , Murai K , Blesch A , Gage FH , Tuszynski MH .	50571
Grill R	50571
Murai K	50580
Blesch A	50589
Gage FH	50599
Tuszynski MH	50608
Cellular delivery of neurotrophin-3	50622
Cellular delivery	50622
neurotrophin-3	50643
corticospinal axonal growth and partial functional recovery	50667
axonal growth	50681
spinal cord injury	50733
J Neurosci 1997b ; 17 : 5560 ± 72 .	50753
J Neurosci 1997b	50753
17 : 5560 ± 72	50771
17 : 5560	50771
72	50780
Gudino-Cabrera G , Pastor AM , de la Cruz RR , Delgado-Garcia JM , Nieto - Sampedro M. Limits to the capacity of transplants of olfactory glia to promote axonal regrowth in the CNS .	50784
Gudino-Cabrera G , Pastor AM , de la Cruz RR , Delgado-Garcia JM , Nieto	50784
Gudino-Cabrera G	50784
Pastor AM , de la Cruz RR , Delgado-Garcia JM , Nieto	50802
Cruz RR , Delgado-Garcia JM	50819
Cruz RR	50819
Delgado-Garcia JM	50828
Sampedro M. Limits to the capacity of transplants of olfactory glia to promote axonal regrowth in the CNS	50854
Sampedro M. Limits	50854
the capacity of transplants of olfactory glia to promote axonal regrowth in the CNS	50876
the capacity	50876
transplants of olfactory glia	50892
transplants	50892
olfactory glia	50907
axonal regrowth	50933
the CNS	50952
Neuroreport 2000 ; 11 : 467 ± 71 .	50961
Neuroreport 2000	50961
11 : 467 ± 71	50979
11 : 467	50979
71	50987
Hantzopoulos PA , Sullenger BA , Ungers G , Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector .	50991
Hantzopoulos PA	50991
Sullenger BA	51008
Ungers G	51022
Gilboa E. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector	51032
Gilboa E. Improved gene expression	51032
transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector	51072
transfer	51072
the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector	51084
the adenosine deaminase minigene	51084
the transcriptional unit of a retroviral vector	51125
the transcriptional unit	51125
a retroviral vector	51153
Proc Natl Acad Sci USA 1989 ; 86 : 3519 ± 23 .	51174
Proc Natl Acad Sci USA 1989	51174
86 : 3519 ± 23	51203
86 : 3519	51203
23	51212
Henderson CE , Phillips HS , Pollock RA , Davies AM , Lemeulle C , Armanini M , et al. .	51216
Henderson CE	51216
Phillips HS , Pollock RA , Davies AM , Lemeulle C , Armanini M , et al.	51230
Phillips HS	51230
Pollock RA	51243
Davies AM	51255
Lemeulle C	51266
Armanini M	51278
et al.	51290
GDNF : a potent survival factor for motoneurons present in peripheral nerve and muscle .	51297
GDNF	51297
a potent survival factor for motoneurons present in peripheral nerve and muscle	51303
a potent survival factor	51303
motoneurons present in peripheral nerve and muscle	51332
motoneurons	51332
peripheral nerve and muscle	51355
Science 1994 ; 266 : 1062 ± 4 .	51384
Science 1994	51384
266 : 1062 ± 4	51398
266 : 1062	51398
4	51408
Ho TW , Bristol LA , Coccia C , Li Y , Milbrandt J , Johnson E , et al. .	51411
Ho TW	51411
Bristol LA , Coccia C , Li Y , Milbrandt J , Johnson E , et al.	51418
Bristol LA	51418
Coccia C	51430
Li Y	51440
Milbrandt J	51446
Johnson E	51459
et al.	51470
TGF-beta trophic factors	51477
motor axon outgrowth and protection	51526
motor axon outgrowth	51526
protection	51551
excitotoxicity	51567
Exp Neurol 2000 ; 161 : 664 ± 75 .	51583
Exp Neurol 2000	51583
161 : 664 ± 75	51600
161 : 664	51600
75	51609
Houenou LJ , Oppenheim RW , Li L , Lo AC , Prevette D. Regulation of spinal motoneuron survival by GDNF during development and following injury .	51613
Houenou LJ	51613
Oppenheim RW	51625
Li L	51639
Lo AC	51645
Prevette D. Regulation of spinal motoneuron survival by GDNF during development and following injury	51652
Prevette D. Regulation	51652
spinal motoneuron survival by GDNF during development and following injury	51678
spinal motoneuron survival	51678
GDNF during development and following injury	51708
GDNF	51708
development and following injury	51720
Cell Tissue Res 1996 ; 286 : 219 ± 23 .	51754
Cell Tissue Res 1996	51754
Cell Tissue	51754
Res 1996	51766
286 : 219 ± 23	51776
286 : 219	51776
23	51785
Imaizumi T , Lankford KL , Burton WV , Fodor WL , Kocsis JD .	51789
Imaizumi T	51789
Lankford KL	51801
Burton WV	51814
Fodor WL	51825
Kocsis JD	51835
Xenotransplantation of transgenic pig olfactory ensheathing cells	51846
Xenotransplantation	51846
transgenic pig olfactory ensheathing cells	51869
axonal regeneration in rat spinal cord	51921
axonal regeneration	51921
rat spinal cord	51944
Nat Biotechnol 2000 ; 18 : 949 ± 53 .	51961
Nat Biotechnol 2000	51961
18 : 949 ± 53	51982
18 : 949	51982
53	51990
Jones LL , Oudega M , Bunge MB , Tuszynski MH .	51994
Jones LL	51994
Oudega M	52004
Bunge MB	52014
Tuszynski MH	52024
Neurotrophic factors , cellular bridges and gene therapy for spinal cord injury .	52038
Neurotrophic factors	52038
cellular bridges and gene therapy for spinal cord injury	52060
cellular bridges and gene therapy	52060
spinal cord injury	52098
J Physiol 2001 ; 533 : 83 ± 9 .	52118
J Physiol 2001	52118
533 : 83 ± 9	52134
533 : 83	52134
9	52142
Kato T , Honmou O , Uede T , Hashi K , Kocsis JD .	52145
Kato T	52145
Honmou O	52153
Uede T	52163
Hashi K	52171
Kocsis JD	52180
Transplantation of human olfactory ensheathing cells	52191
Transplantation	52191
human olfactory ensheathing cells	52210
remyelination of demyelinated rat spinal cord	52252
remyelination	52252
rat spinal cord	52282
Glia 2000 ; 30 : 209 ± 18 .	52299
Glia 2000	52299
30 : 209 ± 18	52310
30 : 209	52310
18	52318
Li L , Wu W , Lin LF , Lei M , Oppenheim RW , Houenou LJ .	52322
Li L	52322
Wu W , Lin LF , Lei M , Oppenheim RW , Houenou LJ	52328
Wu W	52328
Lin LF	52334
Lei M	52342
Oppenheim RW	52349
Houenou LJ	52363
Rescue of adult mouse motoneurons from injury-induced cell death by glial cell linederived neurotrophic factor .	52375
Rescue	52375
adult mouse motoneurons	52385
injury-induced cell death	52414
glial cell	52443
neurotrophic factor	52466
Proc Natl Acad Sci USA 1995 ; 92 : 9771 ± 5 .	52487
Proc Natl Acad Sci USA 1995	52487
92 : 9771 ± 5	52516
92 : 9771	52516
5	52525
Li Y , Field PM , Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells .	52528
Li Y	52528
Field PM	52534
Raisman G. Repair of adult rat	52544
Raisman G. Repair	52544
adult rat	52565
corticospinal tract by transplants of olfactory ensheathing cells	52575
corticospinal tract	52575
transplants of olfactory ensheathing cells	52598
transplants	52598
olfactory ensheathing cells	52613
Science 1997 ; 277 : 2000 ± 2 .	52642
Science 1997	52642
277 : 2000 ± 2	52656
277	52656
2000 ± 2	52661
2000 ±	52661
2	52666
Li Y , Field PM , Raisman G. Regeneration of adult rat corticospinal axons induced by transplanted olfactory ensheathing cells .	52669
Li Y	52669
Field PM	52675
Raisman G. Regeneration of adult rat corticospinal axons induced by transplanted olfactory ensheathing cells	52685
Raisman G. Regeneration	52685
adult rat corticospinal axons induced by transplanted olfactory ensheathing cells	52712
adult rat corticospinal axons	52712
transplanted olfactory ensheathing cells	52753
transplanted olfactory ensheathing	52753
cells	52788
J Neurosci 1998 ; 18 : 10514 ± 24 .	52795
J Neurosci 1998	52795
18 : 10514 ± 24	52812
18 : 10514	52812
24	52822
Lin L-FH , Doherty DH , Lile JD , Bektesh S , Collins F. GDNF : a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons .	52826
Lin L-FH , Doherty DH , Lile JD , Bektesh S , Collins F. GDNF	52826
Lin L-FH	52826
Doherty DH	52836
Lile JD	52848
Bektesh S	52857
Collins F. GDNF	52868
a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons	52885
a glial cell	52885
line-derived neurotrophic factor for midbrain dopaminergic neurons	52898
line-derived neurotrophic factor	52898
midbrain dopaminergic neurons	52935
Science 1993 ; 260 : 1130 ± 2 .	52966
Science 1993	52966
260 : 1130 ± 2	52980
260	52980
1130 ± 2	52985
1130 ±	52985
2	52990
Liu Y , Himes BT , Solowska J , Moul J , Chow SY , Park KI , et al. .	52993
Liu Y	52993
Himes BT , Solowska J , Moul J , Chow SY , Park KI , et al.	53000
Himes BT	53000
Solowska J	53010
Moul J	53022
Chow SY	53030
Park KI	53039
et al.	53048
Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modi ® ed by recombinant retrovirus .	53055
Intraspinal delivery of neurotrophin-3	53055
Intraspinal delivery	53055
neurotrophin-3	53079
neural stem cells genetically modi ® ed by recombinant retrovirus	53100
neural stem	53100
cells genetically modi	53112
cells	53112
recombinant retrovirus	53141
Exp Neurol 1999a ; 158 : 9 ± 26 .	53165
Exp Neurol 1999a	53165
158 : 9 ± 26	53183
158	53183
9 ± 26	53188
9 ±	53188
26	53190
Liu Y , Kim D , Himes BT , Chow SY , Schallert T , Murray M , et al. .	53194
Liu Y	53194
Kim D , Himes BT , Chow SY , Schallert T , Murray M , et al.	53201
Kim D	53201
Himes BT	53208
Chow SY	53218
Schallert T	53227
Murray M	53240
et al.	53250
Transplants of ® broblasts	53257
Transplants	53257
® broblasts	53272
ed	53300
BDNF	53314
regeneration of adult rat rubrospinal axons	53327
regeneration	53327
adult rat rubrospinal axons	53343
recovery of forelimb function	53375
recovery	53375
forelimb function	53387
J Neurosci 1999b ; 19 : 4370 ± 87 .	53406
J Neurosci 1999b	53406
19 : 4370 ± 87	53424
19 : 4370	53424
87	53433
Liu Y , Himes BT , Murray M , Tessler A , Fischer I. Grafts of BDNFproducing ® broblasts rescue axotomized rubrospinal neurons and prevent their atrophy .	53437
Liu Y	53437
Himes BT	53444
Murray M	53454
Tessler A	53464
Fischer I. Grafts of BDNFproducing ® broblasts rescue axotomized rubrospinal neurons and prevent their atrophy	53475
Fischer I. Grafts	53475
® broblasts rescue axotomized rubrospinal neurons and prevent their atrophy	53510
® broblasts rescue	53510
rubrospinal neurons	53539
their atrophy	53571
Exp Neurol 2002 ; 178 : 150 ± 64 .	53586
Exp Neurol 2002	53586
178 : 150 ± 64	53603
178 : 150	53603
64	53612
Menei P , Montero-Menei C , Whittemore SR , Bunge RP , Bunge MB .	53616
Menei P	53616
Montero-Menei C	53625
Whittemore SR	53642
Bunge RP	53657
Bunge MB	53667
Schwann cells	53677
human BDNF	53722
enhanced axonal regrowth across transected adult rat spinal cord	53741
enhanced axonal regrowth	53741
transected adult rat spinal cord	53773
Eur J Neurosci 1998 ; 10 : 607 ± 21 .	53807
Eur J Neurosci 1998	53807
10 : 607 ± 21	53828
10 : 607	53828
21	53836
Mesulam MM .	53840
Mesulam	53840
MM	53848
Tetramethyl benzidine for horseradish peroxidase neurohistochemistry : a non-carcinogenic blue reaction product with superior sensitivity for visualizing neural afferents and efferents .	53852
Tetramethyl benzidine for horseradish peroxidase neurohistochemistry	53852
Tetramethyl benzidine	53852
horseradish peroxidase neurohistochemistry	53878
a non-carcinogenic blue reaction product with superior sensitivity for visualizing neural afferents and efferents	53922
a non-carcinogenic blue reaction product	53922
superior sensitivity for visualizing neural afferents and efferents	53968
superior sensitivity	53968
neural afferents and efferents	54005
J Histochem Cytochem 1978 ; 26 : 106 ± 17 .	54037
J Histochem Cytochem 1978	54037
26 : 106 ± 17	54064
26 : 106	54064
17	54072
Miller AD , Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production .	54076
Miller AD	54076
Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production	54087
Buttimore C. Redesign	54087
retrovirus packaging cell lines	54112
recombination leading	54153
helper virus production	54178
Mol Cell Biol 1986 ; 6 : 2895 ± 902 .	54203
Mol Cell Biol 1986 ; 6	54203
Mol Cell Biol	54203
1986 ; 6	54217
2895 ± 902	54226
2895 ±	54226
902	54231
Oppenheim RW , Houenou LJ , Johnson JE , Lin LF , Li L , Lo AC , et al. .	54236
Oppenheim RW	54236
Houenou LJ , Johnson JE , Lin LF , Li L , Lo AC , et al.	54250
Houenou LJ	54250
Johnson JE	54262
Lin LF	54274
Li L	54282
Lo AC	54288
et al.	54295
Developing motor neurons	54302
cell death	54370
GDNF	54384
Nature 1995 ; 373 : 344 ± 6 .	54390
Nature 1995	54390
373 : 344 ± 6	54403
373 : 344	54403
6	54412
Paratcha G , Ledda F , Ibanez CF. The neural cell adhesion molecule NCAM	54415
Paratcha G	54415
Ledda F	54427
Ibanez CF. The neural cell adhesion molecule NCAM	54436
Ibanez CF. The	54436
neural cell adhesion molecule NCAM	54451
an alternative signaling receptor for GDNF family ligands	54489
an alternative signaling receptor	54489
GDNF family ligands	54527
Cell 2003 ; 113 : 867 ± 79 .	54548
Cell 2003	54548
113 : 867 ± 79	54559
113 : 867	54559
79	54568
Plant GW , Christensen CL , Oudega M , Bunge MB .	54572
Plant GW	54572
Christensen CL	54582
Oudega M	54598
Bunge MB	54608
Delayed transplantation of olfactory ensheathing glia	54618
Delayed transplantation	54618
olfactory ensheathing glia	54645
sparing/regeneration of supraspinal axons in the contused adult rat spinal cord	54681
sparing/regeneration	54681
supraspinal axons in the contused adult rat spinal cord	54705
supraspinal axons	54705
the contused adult rat spinal cord	54726
J Neurotrauma 2003 ; 20 : 1 ± 16 .	54762
J Neurotrauma 2003	54762
20 : 1 ± 16	54782
20 : 1	54782
16	54788
Ramon-Cueto A , Plant GW , Avila J , Bunge MB .	54792
Ramon-Cueto A	54792
Plant GW	54807
Avila J	54817
Bunge MB	54826
Long-distance axonal regeneration in the transected adult rat spinal cord	54836
Long-distance axonal regeneration	54836
the transected adult rat spinal cord	54873
olfactory ensheathing glia transplants	54925
J Neurosci 1998 ; 18 : 3803 ± 15 .	54965
J Neurosci 1998	54965
18 : 3803 ± 15	54982
18 : 3803	54982
15	54991
Ramon-Cueto A , Cordero MI , Santos-Benito FF , Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia .	54995
Ramon-Cueto A	54995
Cordero MI	55010
Santos-Benito FF	55022
Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia	55040
Avila J. Functional recovery of paraplegic rats	55040
Avila J. Functional recovery	55040
paraplegic rats	55072
motor axon regeneration in their spinal cords by olfactory ensheathing glia	55092
motor axon regeneration	55092
their spinal cords by olfactory ensheathing glia	55119
their spinal cords	55119
olfactory ensheathing glia	55141
Neuron 2000 ; 25 : 425 ± 35 .	55169
Neuron 2000	55169
25 : 425 ± 35	55182
25 : 425	55182
35	55190
Rapalino O , Lazarov-Spiegler O , Agranov E , Velan GJ , Yoles E , Fraidakis M , et al. .	55194
Rapalino O	55194
Lazarov-Spiegler O , Agranov E , Velan GJ , Yoles E , Fraidakis M , et al.	55206
Lazarov-Spiegler O	55206
Agranov E	55226
Velan GJ	55237
Yoles E	55247
Fraidakis M	55256
et al.	55269
Implantation of stimulated homologous macrophages	55276
Implantation	55276
stimulated homologous macrophages	55292
partial recovery of paraplegic rats	55337
partial recovery	55337
paraplegic rats	55357
Nat Med 1998 ; 4 : 814 ± 21 .	55374
Nat Med 1998	55374
4 : 814 ± 21	55388
4 : 814	55388
21	55395
Rivlin AS , Tator CH .	55399
Rivlin AS	55399
Tator CH	55410
Objective clinical assessment of motor function after experimental spinal cord injury in the rat .	55420
Objective clinical assessment	55420
motor function	55453
experimental spinal cord injury in the rat	55474
experimental spinal cord injury	55474
the rat	55509
J Neurosurg 1977 ; 47 : 577 ± 81 .	55518
J Neurosurg 1977	55518
47 : 577 ± 81	55536
47 : 577	55536
81	55544
Robbins PD , Ghivizzani SC .	55548
Robbins PD	55548
Ghivizzani SC	55560
Viral vectors for gene therapy .	55575
Viral vectors	55575
gene therapy	55593
Pharmacol Ther 1998 ; 80 : 35 ± 47 .	55607
Pharmacol Ther 1998	55607
80 : 35 ± 47	55628
80 : 35	55628
47	55635
Ruitenberg MJ , Plant GW , Christensen CL , Blits B , Niclou SP , Harvey AR , et al. .	55639
Ruitenberg MJ	55639
Plant GW , Christensen CL , Blits B , Niclou SP , Harvey AR , et al.	55654
Plant GW	55654
Christensen CL	55664
Blits B	55680
Niclou SP	55689
Harvey AR	55700
et al.	55711
Viral vector-mediated gene expression in olfactory ensheathing glia implants in the lesioned rat spinal cord .	55718
Viral vector-mediated gene expression	55718
olfactory ensheathing glia implants	55759
the lesioned rat spinal cord	55798
Gene Ther 2002 ; 9 : 135 ± 46 .	55828
Gene Ther 2002	55828
9 : 135 ± 46	55844
9 : 135	55844
46	55851
Ruitenberg MJ , Plant GW , Hamers FTP , Wortel J , Blits B , Dijkhuizen PA , et al. .	55855
Ruitenberg MJ	55855
Plant GW , Hamers FTP , Wortel J , Blits B , Dijkhuizen PA , et al.	55870
Plant GW	55870
Hamers FTP	55880
Wortel J	55892
Blits B	55902
Dijkhuizen PA	55911
et al.	55926
Ex vivo adenoviral vector-mediated neurotrophin gene transfer to olfactory ensheathing glia : effects on rubrospinal tract regeneration , lesion size , and functional recovery after implantation in the injured rat spinal cord .	55933
Ex vivo adenoviral vector-mediated neurotrophin gene transfer to olfactory ensheathing glia	55933
Ex vivo	55933
adenoviral vector-mediated neurotrophin gene transfer to olfactory ensheathing glia	55941
adenoviral vector-mediated neurotrophin gene transfer	55941
olfactory ensheathing glia	55998
effects on rubrospinal tract regeneration , lesion size	56026
effects	56026
rubrospinal tract regeneration , lesion size	56037
rubrospinal tract regeneration	56037
lesion size	56069
functional recovery after implantation in the injured rat spinal cord	56086
functional recovery	56086
implantation in the injured rat spinal cord	56112
implantation	56112
the injured rat spinal cord	56128
J Neurosci 2003 ; 23 : 7045 ± 58 .	56157
J Neurosci 2003	56157
23 : 7045 ± 58	56174
23 : 7045	56174
58	56183
Schnell L , Schneider R , Kolbeck R , Barde YA , Schwab ME .	56187
Schnell L	56187
Schneider R	56198
Kolbeck R	56211
Barde YA	56222
Schwab ME	56232
Neurotrophin-3	56243
corticospinal tract	56280
development	56307
adult spinal cord lesion	56329
Nature 1994 ; 367 : 170 ± 3 .	56355
Nature 1994	56355
367 : 170 ± 3	56368
367	56368
170 ± 3	56373
170 ±	56373
3	56377
Schwab ME .	56380
the injured spinal cord	56401
Science 2002 ; 295 : 1029 ± 31 .	56426
Science 2002	56426
295 : 1029 ± 31	56440
295 : 1029	56440
31	56450
Takami T , Oudega M , Bates ML , Wood PM , Kleitman N , Bunge MB .	56454
Takami T	56454
Oudega M , Bates ML , Wood PM , Kleitman N , Bunge MB	56464
Oudega M	56464
Bates ML	56474
Wood PM	56484
Kleitman N	56493
Bunge MB	56505
Schwann cell but not olfactory ensheathing glia transplants	56515
Schwann cell	56515
Schwann	56515
cell	56523
olfactory ensheathing glia transplants	56536
hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord	56583
hindlimb locomotor performance	56583
the moderately contused adult rat thoracic spinal cord	56617
adult rat	56641
J Neurosci 2002 ; 22 : 6670 ± 81 .	56673
J Neurosci 2002	56673
22 : 6670 ± 81	56690
22 : 6670	56690
81	56699
Tator CH , Duncan EG , Charles D. Comparisons of the clinical and radiological features and surgical management of posterior fossa meningiomas and acoustic neuromas .	56703
Tator	56703
CH , Duncan EG , Charles D. Comparisons of the clinical and radiological features and surgical management of posterior fossa meningiomas and acoustic neuromas	56709
CH	56709
Duncan EG	56713
Charles D. Comparisons of the clinical and radiological features and surgical management of posterior fossa meningiomas	56724
Charles D. Comparisons of the clinical and radiological features	56724
Charles D. Comparisons	56724
the clinical and radiological features	56750
surgical management of posterior fossa meningiomas	56793
surgical management	56793
posterior fossa meningiomas	56816
acoustic neuromas	56848
J Neurol Sci 1990 ; 17 : 170 ± 6	56871
J Neurol Sci 1990	56871
17 : 170 ± 6	56890
17 : 170	56890
6	56898
Tetzlaff W , Kobayashi NR , Giehl KM , Tsui BJ , Cassar SL , Bedard AM .	56901
Tetzlaff W	56901
Kobayashi NR , Giehl KM , Tsui BJ , Cassar SL , Bedard AM	56913
Kobayashi NR	56913
Giehl KM	56927
Tsui BJ	56937
Cassar SL	56946
Bedard AM	56957
Response of rubrospinal and corticospinal neurons to injury and neurotrophins .	56968
Response	56968
rubrospinal and corticospinal neurons	56980
injury and neurotrophins	57021
Prog Brain Res 1994 ; 103 : 271 ± 86 .	57047
Prog Brain Res 1994	57047
Prog Brain	57047
Res 1994	57058
103 : 271 ± 86	57068
103 : 271	57068
86	57077
Tomac A , Lindqvist E , Lin LF , Ogren SO , Young D , Hoffer BJ , et al. .	57081
Tomac A	57081
Lindqvist E , Lin LF , Ogren SO , Young D , Hoffer BJ , et al.	57090
Lindqvist E	57090
Lin LF	57103
Ogren SO	57111
Young D	57121
Hoffer BJ	57130
et al.	57141
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo .	57148
Protection and repair	57148
the nigrostriatal dopaminergic system by GDNF	57173
the nigrostriatal dopaminergic system	57173
GDNF	57214
vivo	57222
Nature 1995 ; 373 : 335 ± 9 .	57228
Nature 1995	57228
373 : 335 ± 9	57241
373 : 335	57241
9	57250
Tuszynski MH .	57253
Gene therapy for nervous system disease .	57267
Gene therapy	57267
nervous system disease	57284
Ann NY Acad Sci 1997 ; 835 : 1 ± 11 .	57308
Ann NY Acad Sci 1997	57308
835 : 1 ± 11	57330
835 : 1	57330
11	57337
Tuszynski MH .	57341
Neurotrophic factors	57355
Tuszynski MH , Kordower J , editors	57381
Tuszynski MH	57381
Kordower J	57395
editors	57407
CNS regeneration .	57416
CNS	57416
regeneration	57420
San Diego : Academic Press ; 1999 .	57434
San Diego	57434
Academic Press ; 1999	57445
Academic Press	57445
1999	57461
p. 109	57467
58	57474
Tuszynski MH , Weidner N , McCormack M , Miller I , Powell H , Conner J. Grafts of genetically modi ®	57478
Tuszynski MH	57478
Weidner N	57492
McCormack M	57503
Miller I , Powell H	57516
Conner J. Grafts of genetically modi ®	57536
Conner J. Grafts	57536
genetically modi ®	57556
Schwann cells	57576
the spinal cord : survival , axon growth , and myelination	57593
the spinal cord	57593
survival	57610
axon growth	57620
myelination	57637
Cell Transplant 1998 ; 7 : 187 ± 96 .	57650
Cell Transplant 1998	57650
Cell Transplant	57650
1998	57666
7 : 187 ± 96	57672
7 : 187	57672
96	57679
Tuszynski MH , Grill R , Jones LL , Brant A , Blesch A , Low K , et al. .	57683
Tuszynski MH	57683
Grill R , Jones LL , Brant A , Blesch A , Low K , et al.	57697
Grill R	57697
Jones LL	57706
Brant A	57716
Blesch A	57725
Low K	57735
et al.	57742
NT-3 gene delivery	57749
growth of chronically injured corticospinal axons	57776
growth	57776
chronically injured corticospinal axons	57786
de ® cits after chronic scar resection	57859
de ® cits	57859
chronic scar resection	57873
Exp Neurol 2003 ; 181 : 47 ± 56 .	57897
Exp Neurol 2003	57897
181 : 47 ± 56	57914
181 : 47	57914
56	57922
Watabe K , Ohashi T , Sakamoto T , Kawazoe Y , Takeshima T , Oyanagi K , et al. .	57926
Watabe K	57926
Ohashi T , Sakamoto T , Kawazoe Y , Takeshima T , Oyanagi K , et al.	57936
Ohashi T	57936
Sakamoto T	57946
Kawazoe Y	57958
Takeshima T	57969
Oyanagi K	57982
et al.	57993
Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor .	58000
Rescue	58000
lesioned adult rat spinal motoneurons	58010
adenoviral gene transfer of glial cell line-derived neurotrophic factor	58051
adenoviral gene transfer	58051
glial cell line-derived neurotrophic factor	58079
glial cell	58079
line-derived neurotrophic factor	58090
J Neurosci Res 2000 ; 60 : 511 ± 9 .	58124
J Neurosci Res 2000	58124
60 : 511 ± 9	58145
60 : 511	58145
9	58153
Wewetzer K , Verdu E , Angelov DN , Navarro X. Olfactory ensheathing glia and Schwann cells	58156
Wewetzer K	58156
Verdu E	58168
Angelov DN , Navarro X. Olfactory ensheathing glia and Schwann cells	58177
Angelov DN , Navarro X.	58177
Olfactory ensheathing glia and Schwann cells	58200
two of a kind	58246
two	58246
a kind	58253
Cell Tissue Res 2002 ; 309 : 337 ± 45 .	58261
Cell Tissue Res 2002	58261
Cell Tissue	58261
Res 2002	58273
309 : 337 ± 45	58283
309 : 337	58283
45	58292
Whittemore SR , Neary JT , Kleitman N , Sanon HR , Benigno A , Donahue RP , et al. .	58296
Whittemore SR	58296
Neary JT , Kleitman N , Sanon HR , Benigno A , Donahue RP , et al.	58311
Neary JT	58311
Kleitman N	58321
Sanon HR	58333
Benigno A	58343
Donahue RP	58354
et al.	58366
Isolation and characterization of conditionally	58373
Isolation and characterization	58373
astrocyte cell lines derived from adult human spinal cord	58434
astrocyte cell lines	58434
adult human spinal cord	58468
Glia 1994 ; 10 : 211 ± 26 .	58493
Glia 1994	58493
10 : 211 ± 26	58504
10 : 211	58504
26	58512
Woodhall E , West AK , Chuah MI .	58516
Woodhall E	58516
West AK , Chuah MI	58528
West AK	58528
Chuah MI	58537
olfactory ensheathing cells	58556
nerve	58592
growth factor , brain-derived neurotrophic factor , glia cell line-derived neurotrophic factor and their receptors	58598
growth factor	58598
brain-derived neurotrophic factor , glia cell line-derived neurotrophic factor and their receptors	58613
brain-derived neurotrophic factor	58613
glia cell line-derived neurotrophic factor	58648
glia cell	58648
line-derived neurotrophic factor	58658
their receptors	58695
Brain Res Mol Brain Res 2001 ; 88 : 203 ± 13 .	58712
Brain Res Mol Brain Res 2001	58712
Brain	58712
Res Mol Brain Res 2001	58718
88 : 203 ± 13	58742
88 : 203	58742
13	58750
Yan Q , Matheson C , Lopez OT .	58754
Yan Q	58754
Matheson C , Lopez OT	58761
Matheson C	58761
Lopez OT	58773
In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons .	58783
In vivo	58783
neurotrophic effects of GDNF on neonatal and adult facial motor neurons	58791
neurotrophic effects	58791
GDNF on neonatal and adult facial motor neurons	58815
GDNF	58815
neonatal and adult facial motor neurons	58823
Nature 1995 ; 373 : 341 ± 4 .	58864
Nature 1995	58864
373 : 341 ± 4	58877
373 : 341	58877
4	58886
Zhou L , Baumgartner BJ , Hill-Felberg SJ , McGowen LR , Shine HD .	58889
Zhou L	58889
Baumgartner BJ	58897
Hill-Felberg SJ	58913
McGowen LR	58930
Shine HD	58942
Neurotrophin-3	58952
axonal plasticity in the adult injured spinal cord	58993
axonal plasticity	58993
the adult injured spinal cord	59014
J Neurosci 2003 ; 23 : 1424 ± 31 .	59045
J Neurosci 2003	59045
23 : 1424 ± 31	59062
23 : 1424	59062
31	59071
